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Abstract 
This paper assesses critically the science base that underpins the argument that oxidative damage 
is a significant causative factor in the development of human diseases and that antioxidants are 
capable of preventing or ameliorating these disease processes. The assessment has been carried 
out under a number of headings, and some recommendations for future research are made based 
on the present day knowledge base. 
The knowledge database 
(1) Consideration of the basic science that underlies understanding of the role of free radicals in 
causing cellular pathologies, and the role of antioxidants in preventing this, shows that an 
imbalance of reactive oxygen species and antioxidant defence systems may lead to chemical 
modifications of biologically relevant macromolecules. This imbalance provides a logical 
pathobiochemical mechanism for the initiation and development of several disease states. 
Experimental data obtained in vivo provide evidence that antioxidants function in systems that 
scavenge reactive oxygen species and that these are relevant to what occurs in vivo. The relevance 
in vivo of these observations depends inter alia on knowledge of the uptake and distribution of the 
antioxidant within the human body, and on what tissue levels of the antioxidant may be expected 
in relation to dietary levels. 
(2) There is some way to go until validated precise methods are available for measuring 
biomarkers of oxidative damage in human subjects in vivo under minimally invasive conditions. 
With respect to oxidative damage to DNA, HPLC and GC-mass spectrophotometry methods 
have both merits and limitations. Lipid oxidation products in plasma are best measured as 
isoprostanes or as lipid hydroperoxides using specific HPLC techniques. Development of 
isoprostane measurement will advance specificity and precision. The measurement of oxidative 
damage to proteins has some potential but such methods have not been effectively exploited. 
(3) Epidemiological studies support the hypothesis that the major antioxidant nutrients vitamin E 
and vitamin C, and 6-carotene (which may or may not be acting as an antioxidant in vivo), may 
play a beneficial role in prevention of several chronic disorders. More research is needed on the 
impact of other non-nutrient compounds, such as other carotenoids and flavonoids, on human 
health. In general, human intervention studies using hard end-points are the gold standard. Trials 
are restricted mainly to the major antioxidants and do not allow firm conclusions because of 
inconsistent findings, an insufficient number of studies and the use of varying doses. There is 
evidence that large doses of 6-carotene may be deleterious to the health of certain subgroups of 
the population such as heavy habitual smokers. 
(4) With respect to the safety of administration of supplementary vitamins, vitamin C is safe at 
levels of supplementation up to 600 mg/d, and higher levels, up to 2000 mg/d, are without risk. 
Vitamin E has a very low human toxicity and an intake of lOOOmg/d is without risk; 3200 mg/d 
has been shown to be without any consistent risk. Large intakes of &carotene must be viewed 
with caution because they have been shown to confer detriment to a population at high risk of 
lung cancer when administered after many years of high risk (smoking) behaviour. Until further 
work clarifies the situation in heavy smokers with respect to taking supplements, larger doses 
should be avoided by such individuals. There is little reliable information about the human 
toxicology of flavonoids and related non-nutrient antioxidant constituents of the diet. 
Defence against reactive oxidative species s79 
(5) The food industry has long experience in the control of oxidative damage in foods and this 
experience can be used to advantage for the protection of food antioxidants which are beneficial. 
Some of these, such as vitamins C and E and &carotene, are well known, and strategies for their 
protection in foods are already exploited by food technologies. Food technology strategies for the 
preservation of those antioxidants which have been shown to be beneficial to health can be 
applied in a cost-effective manner. 
Research needs 
(1)  The review of the available scientific database enables the identification of areas where further 
research is required. Improvement in dietary antioxidant intake in human populations is expected 
to result in lowering of the risk of a number of degenerative diseases. While desirable as an 
ultimate objective per se, the impact on public health and the resultant decrease in health-care 
costs make it imperative that substantial sums of money should be spent on research in this 
important area. 
(2) Direct measurement of prooxidants in vivo is difficult or impossible. It is imperative to 
establish which are the critical free radical ‘hits’ that are the relevant ones in the aetiology of 
diseases. Are the processes examined really relevant to the disease causation? There is a need to 
identify which are the important antioxidants in terms of the maintenance of health, and what is 
their relationship to one another. Clarification is needed as to whether it is the antioxidant role of 
the substance that is important, or whether it is some other function, and the possible non- 
antioxidant effects of antioxidants, in particular with respect to modulation of gene expression, 
also need further research. The primary aim is to identify the active components in the overall 
system that promote health. 
(3) Ex vivo methodologies for quantitating and validating damage in vivo to biological 
macromolecules urgently need further attention before meaningful work can proceed on 
providing evidence of the level of antioxidants needed to maintain health and well-being. It is 
necessary to refine and validate methods that are already available for measurement of oxidative 
damage in human subjects in a non-invasive manner. Validation in many centres by measurement 
of oxidative damage in the same biological material needs to be undertaken using the same 
methodology. There is a somewhat longer term need for development of techniques to be used ex 
vivo as measures of protein oxidation in vivo. 
(4) Nutritional options modulating oxidative damage. For proper epidemiological research, as 
well as for human intervention studies, it would be desirable to put special emphasis on the 
following. (a) Chemical analysis of the antioxidant content of foods. (b) Studies of bioavailability 
of antioxidants from the diet, and the factors that influence the absorption, distribution and tissue 
uptake of the compounds and the likely impact of the antioxidants on metabolic processes. (c) 
Development and validation of biomarkers of intermediate end-points, both biological response 
markers and early disease markers, and emphasis on the relevance of the biomarker to the disease 
end-point as well as the disease process. (d) Application of the validated biomarkers of 
intermediate end-points in randomized controlled trials testing the efficacy of antioxidants in 
functional foods for the maintenance of health and well-being. 
(5) Safety implications of nutritional enhancement of antioxidants. The detailed evidence that is 
already available which demonstrates that vitamin C and vitamin E are safe at quite high levels of 
inclusion in the human diet, means that is unnecessary to recommend further work in this area. 
The safety of p-carotene was not questioned before the results of the Finnish and American 
intervention studies, which showed an apparent exacerbation in the incidence of lung cancer in 
heavy smokers who were given supplements of /3-carotene. This observation needs urgent 
clarification. With respect to the flavonoids and other polyphenols, it is likely that their 
bioactivity will be explored, and the key question of their bioavailability clarified, in the near 
future. It will be necessary to examine the safety of such bioflavonoid compounds. 
(6) With regard to the role of food technology, there is no particular direction that research needs 
to take at the present time. Developments in food technology will be based on, and adapt to, 
nutritional recommendations resulting from biologically driven work. 
Prooxidants: Antioxidants: Oxidative damage: Diet and health 
‘Good health is more than the mere absence of disease’. Section 2 reviews the basic science concerning free-radical 
Mark Twain damage and the ameliorating role at the cellular level of 
antioxidants, and introduces the concept of maintenance of 
health, and the prevention of some major human degenera- 
tive diseases. In order to assess the extent of free-radical 1. Introduction 
This paper presents a comprehensive assessment of the damage in human subjects in vivo, and the modifying effects 
literature to the end of December 1997 relevant to the role of antioxidants, it is necessary to have valid, precise 
and importance of dietary antioxidants in human health. biomarkers. Present literature on this topic is reviewed in 
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section 3. An account is given in section 4 of the human 
epidemiological and interventional evidence that links a 
high intake of dietary antioxidants with a low risk of 
degenerative disease. If it should be proven with reasonable 
certainty that antioxidants do indeed lower the risk of 
human degenerative disease, it is essential to be sure that 
intervention with antioxidants in the diet, by fortification or 
supplementation of foods, is entirely free from harmful side- 
effects; this important topic is addressed in section 5, and 
the possible contribution of the food industry and food 
technologists to this enhancement is discussed in section 
6. The 7th and 8th sections assess the ‘state of the art’ with 
respect to the foregoing sections and make recommenda- 
tions for research in the immediate future. 
2. Oxidative damage, antioxidant defence and the role of 
prooxidants in disease 
2.1. Antioxidant defence system of the human organism 
2.1.1. Origins and nature of free-radicals and other 
oxidants. The development and existence of an organism 
in the presence of O2 is associated with the generation of 
reactive oxygen species (ROS), even under physiological 
conditions. ROS are responsible for the oxidative damage of 
biological macromolecules such as DNA, carbohydrates and 
proteins (Halliwell & Gutteridge, 1989; Sies, 1991; Halliwell, 
1996). These processes are discussed as pathobiochemical 
mechanisms involved in the initiation or progression phase of 
various diseases (Diplock, 1994; Wiseman & Halliwell, 1996). 
Some of the most relevant ROS are: peroxyl radicals (ROO’), 
the nitric oxide radical PO’), the superoxide anion radical 
(Oi-), singlet oxygen ( 02), peroxynitrite (ONOO-), and 
hydrogen peroxide (H202). ROS are either radicals (molecules 
that contain at least one unpaired electron) or reactive non- 
radical compounds, capable of oxidizing biomolecules. 
Therefore, these intermediates are also called oxidants or 
prooxidants (Halliwell & Gutteridge, 1989; Sies, 1991). 
There are various sources for specific ROS in the human 
organism. However, the superoxide radical anion appears to 
play a central role, since other reactive intermediates are 
formed in reaction sequences starting with 0,. It is 
generated by enzymic one-electron reduction of 0 from 
xanthine oxidase (EC 1.2.3.2), NADPH oxidase, or by 
leakage of the respiratory chain. It has been estimated that 
about 1-3 % of the O2 we utilize is converted to 0;- 
(Fridovich, 1986; Halliwell, 1996). 
H202 is a non-radical reactive species and can easily 
diffuse between living cells. It is efficiently converted to 
water by the enzyme catalase (EC 1.1 1.1.6), a process which 
determines its half-life. Recent evidence suggests that H202 
is involved in signal transduction regulating the expression 
of genes through the nuclear factor KB and apoprotein-1 
pathways (Schreck & Baeuerle, 1994; Sen & Packer, 1996). 
The most reactive species is the hydroxyl radical with 
an estimated half-life of about lop9 s. It might be formed 
in vivo on high-energy irradiation (e.g. X-rays) by homo- 
lytic cleavage of body water or from endogenous H202 in 
metal-catalysed processes (Fenton reaction: Fe-catalysed 
Haber-Weiss reaction). u.v.-Light is insufficiently 
energetic to split water but it can cleave H202 to yield 
two molecules of the hydroxyl radical. The high reactivity 
of this radical implies immediate reaction at the place where 
it is generated. 
The peroxyl radical (ROO’) is relatively long lived 
(seconds) with a considerable diffusion pathlength in bio- 
logical systems. It can be generated in the process of lipid 
peroxidation which is initiated by the abstraction of an H 
atom from polyunsaturated fatty acids (PUFA); the hydro- 
xyl radical is capable of starting this reaction sequence 
(Esterbauer et al. 1992; Reaven & Witzum, 1996). 
Further products generated in lipid peroxidation are 
alkoxyl radicals (RO’) and organic hydroperoxides 
(ROOH). The latter might rearrange to endoperoxide inter- 
mediates which are cleaved to yield aldehydes. The reaction 
of aldehydes with amine groups of proteins has been 
discussed as a mechanism involved in the modification of 
the protein part of lipoproteins. 
Singlet molecular oxygen (lo2) is another non-radical 
ROS which is suggested to be formed in vivo in light- 
exposed tissue. Its half-life has been estimated to be s 
depending on the nature of the surrounding matrix. O2 can 
interact with other molecules either by transferring its 
excitation energy or by combining chemically. Preferential 
targets for chemical reactions are double bonds; e.g. in 
PUFA or guanine in DNA bases (Kanofsky, 1989; Stahl & 
Sies, 1993; Cadet et al. 1994). 
An interesting ROS which has attracted attention within 
the past few years is the nitric oxide radical (NO’). It is a 
signalling compound formed enzymically from arginine and 
relaxes smooth muscles in blood-vessel walls resulting in 
lowered blood pressure. It is also produced by activated 
macrophages contributing to the primary immune defence. 
An excess of NO’ is cytotoxic. It might react directly with 
biomolecules or combine with 0;- to form peroxynitrite 
(ONOO-). Peroxynitnte is capable of inducing lipid per- 
oxidation in lipoproteins but might also interfere with 
cellular signalling by nitrating tyrosine residues in proteins 
(Beckman, 1996; Packer, 1996). 
The ROS described here, and also the biological path- 
ways for their endogenous formation, are examples of a 
whole class of reactive intermediates and their ways of 
generation. It should further be noted that the organism is 
also exposed to ROS from external sources. With the diet 
many compounds of prooxidant nature, such as quinones 
capable of redox cycling, are delivered to the organism. Also 
an array of radicals are inhaled with cigarette smoke; ozone, of 
which increasing levels are reported due to air pollution, is an 
ROS which can oxidize lipids (Pryor et al. 1995). 
ROS are also produced in the organism as a part of the 
primary immune defence. Phagocytic cells such as neutro- 
phils, monocytes, or macrophages defend against foreign 
organisms by synthesizing large amounts of 0;- or NO as a 
part of their killing mechanism. Several diseases are accom- 
panied by excessive phagocyte activation resulting in tissue 
damage which is at least in part due to the activity of ROS. 
2.1.2. Enzymic and non-enzymic defence systems in vivo. 
To counteract the prooxidant load a diversity of antioxidant 
defence systems are operative in biological systems 
including enzymic and non-enzymic antioxidants. An 
antioxidant has been defined as ‘any substance that, when 
present in low concentrations compared to that of an 
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oxidizable substrate, significantly delays or inhibits the 
oxidation of that substrate’ (Halliwell & Gutteridge, 1989; 
Sies, 1993; Halliwell, 1995). 
The major enzymes directly involved in the detoxification 
of ROS are superoxide dismutase (EC 1.15.1. l), scavenging 
Oi-, as well as catalase and glutathione peroxidases (EC 
1.1 1.1.9) which reduce H202 and organic hydroperoxides 
respectively. Several subtypes of glutathione peroxidase are 
Se-dependent. In animal studies an elevated intake of Se 
was associated with protective effects against cancer. Its 
preventive effects in man are still under investigation 
(Levander & Burk, 1996). Indirect antioxidant functions 
are mediated by enzymes that restore endogenous anti- 
oxidant levels; e.g. GSH levels are replenished on reduction 
of GSSG by glutathione reductase (EC 1.6.4.1). Further, 
reactive intermediates produced in reactions of prooxidants 
and biological molecules (e.g. epoxides) are conjugated by 
phase I1 detoxification enzymes such as g1utathione-S- 
transferases (EC 2.5.1.18) to favour their excretion. Another 
strategy to prevent the formation of ROS is the control of the 
levels of free Fe or Cu ions. Metal-binding proteins respon- 
sible for the transport of these ions bind them tightly, thus 
preventing the initiation of lipid peroxidation or DNA 
damage. Some of the most relevant metal-binding proteins 
are ferritin, transferrin, and caeruloplasmin. 
Various endogenous low-molecular-mass compounds are 
also involved in antioxidant defence. GSH, the major 
cytosolic thiol, serves as a cofactor for several detoxifying 
enzymes (glutathione peroxidases, glutathione-S-trans- 
ferases), is involved in the reduction of protein disulfides 
and additionally scavenges ROS, being oxidized to GSSG. 
Other endogenous compounds such as ubiquinol- 10, urate, 
or bilirubin also exhibit antioxidant activities (Jacob & 
Burri, 1996). 
2.1.3. Dietary antioxidants; nutrient and non- 
nutrient. The human diet contains an array of different 
compounds that possess antioxidant activities or have been 
suggested to scavenge ROS based on their structural 
properties. The most prominent representatives of dietary 
antioxidants are ascorbate (vitamin C), tocopherols (vitamin 
E), carotenoids, and flavonoids. Apart from vitamin C, each 
group of these antioxidants consists of a number of 
structurally different compounds; e.g. more than 600 
different carotenoids have been identified to date and 
about fifty of them might occur in the human diet (Sies & 
Stahl, 1995; Rice-Evans & Miller, 1996; Rock et al. 1996). 
In the diet, there may be synergistic effects of these various 
dietary compounds which are difficult to assess at present. 
Indeed, the diet may be considered as an orchestra where 
interactions between constituents may bring about effects 
which are not the necessary properties of the individual 
constituents. 
Vitamin C is considered to be one of the most powerful, 
least toxic natural antioxidants (Bendich et al. 1986; Weber 
et al. 1996). It is water-soluble and is found in high 
concentrations in many tissues; human plasma contains 
about 60pmol ascorbateA. On interaction with ROS it is 
oxidized to dehydro-ascorbate via the intermediate ascorbyl 
free radical. Dehydro-ascorbate is recycled back to ascorbic 
acid by the enzyme dehydro-ascorbate reductase. Thus, 
dehydro-ascorbate is found in only very low levels 
compared with ascorbate. As a scavenger of ROS ascorbate 
has been shown to be effective against the superoxide 
radical anion, H202, the hydroxyl radical, and singlet 
oxygen. In aqueous solutions vitamin C also scavenges 
reactive nitrogen oxide species efficiently, preventing the 
nitrosation of target molecules. The major sources of 
ascorbate in the diet are fruits, especially citrus fruits, 
kiwi fruit, cherries and melons, and vegetables such as 
tomatoes, leafy greens, broccoli, cauliflower, Brussels 
sprouts, and cabbage; its content might exceed 100mg 
ascorbate/100 g fresh weight. At low dose levels (100 mg) 
the bioavailability values for vitamin C from synthetic and 
food sources are very similar (Mangels et al. 1993a); the 
efficacy of absorption decreases with increasing dose levels 
(Levine et al. 1996). There is evidence from studies in vitro 
that vitamin C is capable of regenerating tocopherol from 
the tocopheroxyl radical which is formed on inhibition of 
lipid peroxidation by vitamin E (Niki et al. 1982, 1985). 
This process would allow for the transport of a radical load 
from a lipophilic compartment to an aqueous compartment 
where it is taken care of by efficient enzymic defence 
systems. It should be noted, however, that ascorbate might 
also act as a prooxidant in vivo. In the presence of free 
transition metal ions (Fe and Cu) and ascorbate the hydroxyl 
radical can be generated and initiation of lipid peroxidation 
may occur. However, the amounts of free transition metals 
in vivo are very small because they are efficiently bound to 
proteins. Vitamin C has additional well-established biolo- 
gical functions including cofactor-activity for several 
important enzymes (Levine et al. 1996). 
The term vitamin E is a generic description for all tocols 
and tocotnenol derivatives which exhibit the biological 
activity of a-tocopherol (Parker, 1989; Eldin & Appelqvist, 
1996; Sokol, 1996; Traber & Sies, 1996). This group of 
compounds is highly lipophilic, and operative in membranes 
or lipoproteins. Their most important antioxidant function 
appears to be the inhibition of lipid peroxidation, scaven- 
ging lipid peroxyl radicals to yield lipid hydroperoxides and 
a tocopheroxyl radical. The latter is less reactive than 
peroxyl radicals towards neighbouring PUFA and acts as a 
chain-breaking antioxidant. The tocopheroxyl radical might 
be either reduced by ascorbate and GSH or further oxidized 
to the respective quinone. Since only small amounts of 
tocopheryl quinone are detectable in human blood and 
tissues, the regenerative pathway in vivo appears to be 
favoured. In comparison with other lipophilic antioxidants, 
a-tocopherol is probably the most efficient in the lipid phase 
(Niki, 1987). It contains shielding methyl groups adjacent to 
the phenolic hydroxyl group and it is optimally positioned in 
membranes by its phytyl side-chain, which is located in the 
hydrophobic region of the membrane structure. In addition 
to its peroxyl-radical scavenging properties, further interac- 
tions with ROS have been described, including quenching of 
singlet oxygen and interaction with peroxynitrite. The 
richest sources of vitamin E in the diet are vegetable oils 
(soyabean, maize, cottonseed, and safflowerseed), and pro- 
ducts made from these oils such as margarine and mayon- 
naise. Further, wheat germ, nuts, and some green leafy 
vegetables contribute considerable amounts to the vitamin 
E supply (Parker, 1989). Vitamin E plasma levels in man are 
about 22 pmolA; the compound is also found in tissues such 
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as liver, kidney, fat and adrenals. In the liver the RRR- 
isomer of a-tocopherol is preferentially incorporated into 
VLDL which are further catabolized in the circulation. 
Thus, RRR-a-tocopherol is the major form of vitamin E 
in LDL (Traber & Sies, 1996). 
Carotenoids are natural colourants with pronounced anti- 
oxidant activity (Stahl & Sies, 1993; Olson & Krinsky, 
1995). Their chemical properties are closely related to the 
presence of an extended system of conjugated double bonds 
which is substituted with various endgroups. ROS which are 
efficiently scavenged by carotenoids are lo2 and peroxyl 
radicals (Palozza & Krinsky, 1992). Two different pathways 
are operative with respect to the deactivation of lo2: 
physical and chemical quenching (Truscott, 1990). Physical 
quenching implies the deactivation of lo2 by energy trans- 
fer from the excited oxygen species to the carotenoid, 
yielding a triplet excited carotenoid. The energy of the 
excited carotenoid is dissipated through vibrational interac- 
tions with the solvent to recover ground state carotenoid. 
The carotenoid remains intact in this process and might 
undergo further cycles of deactivation. Chemical quenching 
contributes less than 0.05% to total '02-quenching by 
carotenoids but is responsible for the eventual destruction 
of the molecule. Carotenoids are the most efficient naturally 
occumng quenchers for lo2 with quenching rate constants 
of about 5-12 x 109/m01 per s. Carotenoids were reported to 
scavenge peroxyl radicals by chemical interaction (Kennedy 
& Liebler, 1992). It is suggested that carotene radical 
intermediates are formed in this process which finally 
leads to the destruction of the molecule. Like vitamin E, 
carotenoids belong to the group of lipophilic antioxidants 
present in lipoproteins such as LDL and HDL. It has been 
shown that they are consumed when isolated LDL is 
exposed to the process of lipid peroxidation. Their contribu- 
tion to the antioxidant defence system of LDL is not clear, 
since no regeneration pathways for oxidized carotenoids are 
known at present. A variety of structurally different caroten- 
oids are present in fruits and vegetables. Some of the major 
sources are carrots (a-carotene, @-carotene), tomatoes 
(lycopene), citrus fruits (0-cryptoxanthin), spinach 
(lutein), and maize (zeaxanthin) (Mangels et al. 1993b). 
The absorption and transport processes of carotenoids are 
quite complex. Several factors influencing carotenoid bio- 
availability from food, such as co-ingestion of fat or fibre, 
cooking or food processing, have been identified (Erdman et 
al. 1993). 
Flavonoids are a large group of polyphenolic antioxidants 
that occur in several fruits, vegetables, and beverages such 
as tea, wine and beer mainly as 0-glycosides. They are 
efficient antioxidants capable of scavenging radical species 
(peroxyl radicals, hydroxyl radical, Oi-) forming a phenoxy 
radical (Rice-Evans et al. 1995; Rice-Evans & Miller, 
1996). The term flavonoids summarizes a number of 
structurally different subgroups including flavanols (cate- 
chin, epicatechin), flavonols (quercetin, myricetin, kaem- 
pherol), flavanones (naringenin, taxifolin), flavones 
(apigenin, hesperetin), isoflavones (genestein), or antho- 
cyanidins (cyanidin, malvidin). Several criteria for optimal 
radical scavenging properties of flavonoids have been 
postulated based on pulse radiolysis studies. These include 
the presence of the 3',4'-dihydroxy structure in ring B, the 
presence of the 2,3-double bond in conjugation with the 4- 
0x0-group in ring C, and the presence of a 5-hydroxyl group 
in ring A with a 3-hydroxyl group and a 4-0x0 function in 
the C-ring. The antioxidant properties of flavonoids have 
been investigated in various studies in vivo and in vitro. It 
should be mentioned, however, that the bioavailability of 
these compounds is rather poor. They are rapidly conjugated 
in phase I1 detoxification reactions and levels of free 
flavonoids in human plasma are very low. Further phenolic 
compounds with antioxidant activity are derivatives of 
cinnamic acid; e.g. caffeic acid, chlorogenic acid, and 
ferulic acid (Rice-Evans & Miller, 1996). 
In addition to the flavonoids, a number of other phenolic 
compounds of potential interest occur in foods. Thus, olive 
oil contains a number of phenolic substances, notably the o- 
diphenol tyrosol, which may contribute to the antioxidant 
content of diets rich in olive oil (Kiritsakis, 1990). Similarly, 
plants of the Lamiaceae family, notably rosemary, oregano, 
sage, mint and thyme, contain a range of potential antiox- 
idants such as carnosol, rosemanol and carvacrol, which can 
contribute to the antioxidant potential of the diet (Lagouri & 
Boskou, 1996). As with the flavonoids, however, little is 
known of the human absorption and tissue distribution of 
these compounds. 
Several other dietary constituents might also be involved 
in the antioxidant defence system either by direct action as 
antioxidants or by effects related to the induction of detox- 
ifying enzymes. Enzymes such as glutathione peroxidase 
and superoxide dismutase, which require a dietary supply of 
Se, and of Cu and Zn respectively, contribute to the overall 
oxidative defence mechanism. Some endogenous sub- 
stances such as urate also add to the antioxidant potential 
of living cells, although their significance is only speculat- 
ive. Enhancement of dietary intake of the minerals identified 
may be beneficial when their content in the diet is low. 
2.2. Oxidative damage to bodily functions and its 
implications in disease 
ROS are suggested, or known, to be involved in pathogenic 
processes of numerous diseases (Esterbauer et al. 1992; Luis 
& Navab, 1993; Diplock, 1994; Sies, 1997) such as 
cardiovascular disease, some forms of cancer, cataract, 
age-related macular degeneration, rheumatoid arthritis and 
a number of neurodegenerative diseases. Oxidative damage 
to important biomolecules is a deleterious pathway, but also 
influences of ROS on gene regulation or the immune 
system might impair bodily functions. There is increasing 
evidence from clinical and intervention studies, as well 
as from basic research that antioxidants might prevent 
or delay the development of disease states. There may 
also be particular population groups that will benefit from 
enhanced antioxidant intake, such as pregnant women, 
neonates and children, senior citizens and, perhaps, 
sportspeople. 
The primary cause for 
most cardiovascular diseases is thought to be arterio- 
sclerosis, a multifactorial disease of the artery wall. It is 
suggested that in the early stages of arteriosclerosis lipid 
deposits, so-called fatty streaks, are formed in the 
subendothelial space. There is increasing evidence that 
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oxidative stress, particularly oxidation of LDL, is a risk 
factor and plays a role in the pathogenic pathway (Berliner 
& Heinecke, 1996). LDL oxidation is due to a lipid 
peroxidation reaction initiated by free radicals. Separate 
investigations of the lipid and protein parts of oxidized LDL 
demonstrated that oxidative modifications of both contrib- 
ute to the proatherogenic properties of oxidized LDL. 
Several biochemical mechanisms underlying this effect 
have been discussed. These include the formation of foam 
cells on the uptake of oxidized LDL via the scavenger 
receptor by macrophages resident in the subendothelial area, 
release of cytotoxic lipid peroxidation products from 
oxidized LDL, or chemoattractant properties of the oxidized 
lipoprotein. LDL oxidation is efficiently inhibited by 
lipophilic antioxidants of which a-tocopherol appears to 
be the most important. Epidemiological studies suggest 
preventive effects towards atherogenic lesions to be 
associated with an increased uptake of lipophilic antiox- 
idants such as vitamin E or carotenoids (Rimm et al. 1993). 
Additional effects of RRR-a-tocopherol, independent of 
its antioxidant activity, have been related to the protective 
properties of this compound. An early event in the onset of 
arteriosclerosis is the migration of smooth-muscle cells 
from the media to the intima of the arterial wall followed 
by proliferation of these cells. There is increasing evidence 
that RRR-a-tocopherol acts as a negative regulator of 
smooth-muscle cell proliferation via modulation of protein 
kinase C activity. Protein kinase C is an important element 
in the signal transduction cascade mediated by growth 
factors such as platelet-derived growth factor which are 
involved in the control of cell proliferation. It should be 
noted that these effects are limited to RRR-a-tocopherol; 
RRR-0-tocopherol does not inhibit protein kinase C (Azzi et 
al. 1995; Ozer et al. 1995). 
2.2.2. Curcinogenesis. Carcinogenesis is a complex 
multistep process including initiation, promotion and 
progression. The generation of ROS is thought to be 
linked to tumourigenesis at different levels. Oxidative 
damage to DNA has been demonstrated in vitro and in 
vivo leading to DNA single or double strand breaks and 
DNA cross linking, as well as to chromosomal aberrations 
such as breakage or rearrangement. Modified DNA bases 
(e.g. hydroxythymidine, or hydroxyguanine) have been 
determined after exposure of cells to situations of oxidative 
stress. The modification of DNA bases might result in point 
mutations, deletions, or gene amplification as a first step of 
carcinogenesis. Further, ROS are capable of deactivating 
detoxifying enzymes responsible for the scavenging of 
potent carcinogens. Data from epidemiological studies 
support the idea that antioxidants are preventive in 
carcinogenesis by scavenging ROS (Flagg et al. 1995). 
Carotenoids exhibit further biological functions which 
are not related to their antioxidant activities but might be of 
importance with respect to their cancer preventive effects 
(Gerster, 1995). It has been shown that provitamin A and 
non-provitamin A carotenoids are capable of inhibiting the 
growth of transformed fibroblasts (Bertram & Bortkiewicz, 
1995). There is increasing evidence that growth arrest is due 
to the stimulation of gap-junctional communication 
between transformed and surrounding normal cells. These 
findings suggest that carotenoids or carotenoid-derived 
retinoids play a role in intercellular signalling involved in 
growth control. Inhibitory effects of &carotene and lyco- 
pene on cell proliferation have also been described for 
several human cancer cell lines (Sharoni & Levy, 1996). 
2.2.3. Cataract and age-related macular degeneration. 
Oxidative damage and impaired vision have been discussed 
in the context of two ophthalmological diseases of the elderly, 
cataract and age-related macular degeneration (AMD) 
(Schalch, 1992; Taylor, 1993). Senile cataract indicates the 
opacity of ocular lenses. Lens proteins are extremely long- 
lived and often show oxidative damage. This is not surprising, 
since they are subjected to chronic exposure to light and 02, 
which is likely to be responsible for the formation of ROS 
which might react with lens proteins. As a consequence, the 
damaged proteins may aggregate and precipitate, thus losing 
their regular function. Supplementation studies support the 
hypothesis that a higher intake of vitamins including vitamin 
C and vitamin E prevents or delays the development of 
cataracts (Seddon et al. 1994b). 
AMD is the major cause of visual impairment in Western 
countries and affects the anatomical region of the retina with 
the highest degree of visual activity. The macular pigment 
(yellow spot) represents a colour filter through which light 
must pass before detection. The carotenoids lutein and 
zeaxanthin are the predominant pigments in this area (Land- 
rum, 1997). Carotenes (hydrocarbon carotenoids) are not 
present in the yellow spot. The function of the macular 
pigment has not been unequivocally identified but it might 
protect against photo-oxidation by blue light, mediated by 
excited triplet state molecules, lo2, or superoxide. There are 
hints from food-frequency questionnaires that an increased 
consumption of food rich in lutein and zeaxanthin is 
associated with a diminished risk of AMD (Seddon et al. 
1994~).  Carotenoids are the most efficient natural com- 
pounds scavenging O2 and excited triplet state molecules. 
Growing data from experi- 
mental models and human brain studies add evidence that 
oxidative stress might play a role in the development of 
neuronal degeneration related to diseases such as Parkin- 
son’s disease, amyotrophic lateral sclerosis, and Alzhei- 
mer’s disease (Kondo, 1996; Simonian & Coyle, 1996). 
ROS are capable of inducing both necrosis and apoptosis. 
As a consequence of lipid peroxidation membrane rupture 
might occur or ion gradients, operative over compartments 
which are separated by membranes, might be disturbed. 
Neurons might undergo necrotic cell death as has been 
demonstrated in cell culture following depletion of 
intracellular GSH, the major endogenous antioxidant thiol. 
NO has been hypothesized to be an important mediator of 
neuronal death under pathological conditions. The ultimate 
species responsible for NO toxicity may be peroxynitrite 
which is formed by the reaction of the NO-radical with the 
superoxide radical. 
Beyond the classical aspects of oxidative damage to 
biologically relevant molecules as pathological mechanisms 
underlying several diseases, and the protective effects of 
antioxidants, new fields of research in this area are rapidly 
developing. This includes effects of prooxidants and anti- 
oxidants on immune functions (Bendich, 1990) and antiox- 
idant and redox regulatory properties on gene expression. 
Both mechanisms may be involved in the development of 
2.2.4. Neuronal diseases. 
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disease states while protection might be provided by 
antioxidants via these pathways. 
2.3. Conclusions 
An imbalance between ROS and antioxidant defence sys- 
tems may lead to chemical modifications of biologically 
relevant macromolecules like DNA, proteins or lipids which 
are possible pathobiochemical mechanisms in the initiation 
or development of several disease states. Experimental data 
provide evidence that dietary antioxidants scavenge ROS 
and are useful in the prevention of these diseases. Epi- 
demiological studies clearly show a correlation between the 
increased consumption of food rich in antioxidants and a 
decreased risk of several diseases. Thus, an increased intake 
of fruits and vegetables can be recommended. Data on 
antioxidant supplementation are contradictory. Further 
research is necessary to establish whether supplementation 
beyond dietary intake levels is of benefit. 
3. Available methodologies for evaluating and 
quantifying ex vivo damage to DNA, lipids and proteins 
by prooxidants in vivo 
3.1. Oxidative damage to DNA 
The most abundant base alteration induced in DNA by ROS 
is the formation of 8-0~0-7,8-dihydro-2’-deoxyguanine (8- 
oxodG). In vivo this DNA base alteration is repaired by 
excision and the resulting product 8-oxodG is excreted 
unchanged, and independently of diet, into the urine. 
Thus, the rate of excretion of 8-oxodG (as given by the 
appearance of the metabolite in urine with time) serves as a 
biological marker of the integrated rate of oxidative DNA 
damage in the whole body. 
DNA damage is usually measured in lymphocytes iso- 
lated from blood or in urine. Baseline levels of DNA 
damage are considered to be important because repair 
may be incomplete (one damaged base per lo6 bases); the 
actual measurement may therefore provide an estimate of 
the balance between damage and repair, so the time window 
is a crucial consideration here. From studies in vitro it is 
known that when DNA is exposed to the activated oxygen 
species the product is specific to the oxygen species 
involved, thus: 
lo2, ROO’ - guanine oxidized 
‘OH - multiplicity of changes to all four bases 
O, H202 - no base changes 
ONOO- - xanthine, hypoxanthine, 8-nitroguanine. 
There are two types of measurement of oxidative DNA 
damage. First, steady-state damage can be measured when 
DNA is isolated from human cells and tissues and analysed 
for base damage products: it presumably reflects the balance 
between damage and DNA repair. Hence a rise in steady- 
state oxidative DNA damage (e.g. as has been reported in 
some human cancerous tissues; Malins & Haimonot, 1991; 
Olinski et al. 1992) could be due to increased damage and/or 
decreased repair. Second, several DNA base damage pro- 
ducts are excreted in human urine, including the nucleoside 
8-hydroxy-deoxyguanosine (8-OHdG), 8-hydroxy-adenine 
and 7-methyl-8-hydroxyguanine (Ames, 1989; Stillwell et 
al. 1989) but the one most exploited is 8-OHdG, usually 
measured by a method involving HPLC with electrochem- 
ical detection (Ames, 1989; Shigenaga et al. 1994). 
The validity of these urinary measurements of oxidative 
DNA damage must be considered. The level of 8-OHdG in 
urine is presumably unaffected by the diet since nucleosides 
are not absorbed from the gut. The question of whether any 
8-OHdG is metabolized to other products in man has not 
been rigorously addressed. Additionally, it is possible that 
some or all of the 8-OHdG excreted in urine may arise not 
from DNA, but from deoxyGTP in the DNA precursor pool 
of nucleotides. An enzyme has been described which 
hydrolyses deoxyGTP containing oxidized guanine to pre- 
vent its incorporation into DNA (Mo et al. 1992; Sakumi et 
al. 1993). These uncertainties require clarification. 
3.1. I .  Measurement of guanine damage products in DNA 
by HPLC and gas chromatography-mass spectrometry 
(GC-MS). As mentioned earlier, 8-hydroxyguanine (8- 
OHG) and 8-OHdG are the products most frequently used as 
indicators of oxidative DNA damage. Analysis of 8-OHdG 
using HPLC coupled to electrochemical detection (Floyd et 
al. 1986), is a highly sensitive technique that is frequently 
used after release of 8-OHdG from DNA, usually by 
enzymic hydrolysis. GC-MS with selective ion monitoring 
has also been used to characterize oxidative DNA base 
damage by the identification of a spectrum of products 
(Dizdaroglu, 1993a), including 8-OHG, after formic acid 
hydrolysis of DNA and derivatization (often by trimethyl- 
silylation) to generate volatile products. When GC-MS is 
used to measure modified DNA bases, a quantitative 
analysis of these bases in a DNA sample can be achieved 
by adding a suitable internal standard to that sample at an 
early stage of the analysis, such as before the hydrolysis of 
the DNA (Dizdaroglu, 1993b). Stable-isotope-labelled 
analogues of the modified bases can also be used as internal 
standards (Dizdaroglu, 19936). 
One advantage of the GC-MS approach is that measure- 
ment of a wide range of base damage products allows more 
accurate quantification of DNA damage and can help to 
identify the ROS and reactive nitrogen species (RNS) 
that caused the damage (Malins & Haimonot, 1991); 
O2 selectively attacks guanine whereas OH’ attacks all 
four DNA bases. However, the levels of 8-OHdG measured 
in DNA by HPLC with electrochemical detection are often 
(Halliwell & Dizdaroglu, 1992) (but not always; Lunec 
et al. 1994; Herbert et al. 1996) less than the levels of 
8-OHG measured by GC-MS with selective ion monitor- 
ing. HPLC could underestimate the real amount of 8- 
OHdG in DNA if the enzymic hydrolysis was incomplete; 
the action of the exonucleases and endonucleases used to 
hydrolyse the DNA may be affected by the modification of 
the bases (Halliwell & Dizdaroglu, 1992; Turk & 
Weitzman, 1995) and the acid pH often used for nuclease 
digestions might induce hydrolysis of 8-OHdG to 8-OHG, 
resulting in the loss of HPLC-detectable material. In 
contrast, GC-MS might overestimate 8-OHG (and perhaps 
other base damage products) as a result of their artifactual 
formation during the heating step involved in classical 
silylation-based derivatization procedures (Halliwell & 
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Dizdaroglu, 1992; Ravanat et al. 1995). A ‘cold’ derivatization 
procedure has been developed that should avoid this 
problem (Hamberg & Zhang, 1995). The important factor 
is that any necessary heating stages should be done 
anoxically: heating DNA bases in the presence of O2 
inevitably results in oxidation. Hence some of the claimed 
artifacts (Hamberg & Zhang, 1995; Ravanat et al. 1995), 
are possibly due to failure to remove 02. However, it is 
difficult to remove O2 completely. Indeed, a major problem 
to be considered in all these techniques is the possibility 
that DNA is oxidatively damaged during its isolation from 
cells and tissues, particularly if phenol-based methods are 
used, since oxidizing phenols generate ROS (Claycamp, 
1992; Finnegan et al. 1996). However, rigorous control of 
isolation procedures and avoidance of phenol in many labora- 
tories (e.g. by studying isolated chromatin or by using 
different DNA isolation methods) does not abolish oxidative 
damage detected in isolated DNA (Halliwell & Dizdaroglu, 
1992; Dizdaroglu, 1993a; Harris et al. 1994; Shigenaga et al. 
1994; Finnegan et al. 1996), strongly supporting the view that 
there is a low steady-state DNA damage in vivo. Indeed the 
presence of a DNA repair enzyme system and the excretion of 
base damage products support the view that oxidative damage 
really does occur in vivo. 
As an alternative means of avoiding possible problems 
with derivatization an HPLC method with electrochemical 
detection has been developed that allows measurement of 8- 
OHG and three of the other oxidized base products in acid- 
hydrolysed DNA, thus avoiding the need for derivatization. 
Liquid chromatography-mass spectrometry techniques are 
under development in several laboratories: this is another 
approach to avoiding derivatization problems if sufficient 
sensitivity can be achieved. 
3.2. Oxidative damage to lipids 
3.2.1. Lipid peroxidation. There is a range of methods 
available for measurement of markers of lipid peroxidation 
and products of peroxidation in vivo that can be measured in 
blood and urine as indicators of oxidative stress. There are, 
however, a number of problems that need to be resolved 
before it is possible to be confident that measurements made 
are valid and reproducible, and inter-laboratory studies 
using the same reference material are urgently needed to 
resolve the remaining difficulties. These include variability 
of the standards used, and small differences in the technique 
employed which can have a marked effect on the result 
achieved; furthermore, no single method can, by itself, 
provide an unambiguous indicator of levels of lipid 
peroxidation, whether by measuring lipid hydroperoxides, 
or degradation products therefrom. 
Evidence for damage to lipids in vivo is derived from 
measurement of peroxides or isoprostanes in blood and 
urine. Such indicators of peroxides in vivo are important 
vis-2-vis, for example, the relationship of plasma peroxides 
to vessel wall oxidation of LDL in the context of athero- 
sclerosis. The major problem which has yet to be addressed 
with some consolidated approach is the differentiation in 
identification of peroxides formed as a consequence of in 
vivo oxidative stress and those ingested from dietary 
sources. 
Peroxide levels in cells and tissues present a balance 
between peroxide formation and peroxide metabolism or 
decomposition, i.e. they are essentially a ‘steady-state’ 
measurement. 
With respect to measurement of levels of lipid hydro- 
peroxides, a number of methods are available. Ex vivo 
measurement of the lipid hydroperoxide products directly 
is best achieved by HPLC determination following parti- 
tioning of the hydroperoxide into a polar solvent, which 
achieves a primary separation between less polar triacylgly- 
cerol and cholesterol hydroperoxides and the more polar 
free fatty acids and phospholipid hydroperoxides (Rice- 
Evans et al. 1991). Chemiluminescence-based detection 
has proved very satisfactory in providing a reliable assay 
procedure (Yamamoto, 1994); an alternative is luminol- 
chemiluminescence. 
The steady-state levels of peroxides in human body fluids, 
such as blood plasma, appear very low, usually < 100 nmol/l. 
These data come from assays that measure ‘real’ lipid 
peroxides (Holley & Slater, 1991; Akasaka et al. 1995) 
viz by HPLC with chemiluminescence detection rather than 
notoriously-unspecific methods such as diene conjugation 
or the simple thiobarbituric acid (TBA) test (Halliwell & 
Chirico, 1993). HPLC-based TBA tests can, however, 
record comparably-low values, provided that butylated 
hydroxytoluene is added with the TBA reagents (Halliwell 
& Chirico, 1993). 
Several other different approaches have been used for 
measurements of the lipid hydroperoxide products of 
peroxidation of PUFA. The most simple method concep- 
tually involves direct iodometric determination of lipid 
hydroperoxide. A further alternative is provided by the 
ferrous oxidation in xylenol orange (FOX) method in its 
two variants which provide methods for measuring low 
levels of soluble hydroperoxides in the aqueous phase, or 
lipid hydroperoxides derived from membranes of lipopro- 
teins in the lipid phase (Wolff, 1994). Assays of human 
tissues and body fluids by simple ‘peroxide-determinations’ 
such as those involving xylenol orange (Jiang et al. 1992) or 
iodometric methods (Thomas et al. 1989) could measure 
protein peroxides; this could conceivably explain why 
levels of alleged ‘lipid peroxides’ measured by such tech- 
niques in human body fluids tend to be higher (often in the 
PM range) than those revealed by the more-specific tech- 
niques for measuring lipid peroxides that were discussed 
earlier (see section 3.2.3). 
A more recently introduced type of assay concerns 
measurement of isoprostanes which are derived from 
PUFA by a non-cyclooxygenase-mediated free-radical- 
catalysed mechanism. Formation of the arachidonic acid- 
derived compounds involves formation of four positional 
peroxyl radical isomers of the fatty acid which undergo 
endocyclization to prostaglandin (PG)G2-like compounds 
that are then reduced to PGF2-like compounds. Four F2- 
isoprostane isomers are formed, each of which can, in 
theory, comprise eight diastereoisomers. Quantification of 
F2-isoprostanes represents a reliable and useful approach to 
assessment of lipid peroxidation and oxidant stress in vivo 
(Morrow & Roberts, 1994). 
Human body fluids also contain low levels of F2-isopros- 
tanes, compounds isomeric to prostaglandins that appear to 
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arise by free-radical oxidation of phospholipids containing 
arachidonic acid (Morrow & Roberts, 1994; Morrow et al. 
1995). Isoprostanes appear to exist in human plasma largely 
esterified to phospholipids rather than ‘free’, and sensitive 
assays to measure them have been described (Morrow & 
Roberts, 1994; Wang et al. 1995). Isoprostanes and their 
metabolites can be measured in human urine (Morrow & 
Roberts, 1994; Morrow et ul. 1995) by GC-MS and this 
may prove a valuable assay of whole-body lipid peroxida- 
tion if a confounding effect of diet can be ruled out. These 
compounds are useful ‘markers’ of lipid peroxidation and 
can be measured in plasma (35 (SD 6) pg/ml) and urine 
(1600 (SD 600) pg/mg creatinine) of healthy volunteers, 
indicative of ongoing lipid peroxidation even in healthy 
human subjects (Halliwell, 1996). 
3.2.2. Can some measure of ‘total’ peroxidation be 
obtained? Approaches to measurements of ‘total-body’ 
lipid peroxidation have been by measurements of urinary 
TBA-reactive substances (TBARS), using the HPLC TBA 
method (Chirico & Halliwell, 1994), measurements of 
hydrocarbon gas excretion and by measurements of Fz- 
isoprostanes in urine. Urinary TBARS measurements have 
been found to be confounded by a multiplicity of urinary 
constituents that react with TBA, and this problem is further 
complicated by contributions from dietary constituents, 
particularly cooked meats. Most of the lipid-related TBARS 
appearing in urine seem to arise from lipid peroxides or 
aldehydes in ingested food, which are presumably largely 
generated during cooking (Dhanakoti & Draper, 1987; 
Brown et al. 1995). Hence urinary TBARS is not a suitable 
assay to assess whole-body lipid peroxidation in response to 
changes in dietary composition, although it could theoret- 
ically be used to look at effects of supplementary 
antioxidants in individuals on a standardized ‘fixed diet’ 
(Dhanakoti & Draper, 1987). In any case, HPLC must be 
used to separate the real (TBA), malondialdehyde adduct 
since the majority of the TBARS in urine are not even lipid- 
derived (Gutteridge & Tickner, 1978) or derive from a wide 
variety of aldehydes other than malondialdehyde. 
Measurement of hydrocarbon gases (alkanes and 
alkenes), degradation products of lipid peroxidation in 
vivo (Burk & Ludden, 1989; Springfield & Levitt, 1994), 
can be confounded by interference from air pollutants and 
from the products of gastrointestinal bacterial metabolism. 
They are unreliable also because of the low level of the 
metabolites to be measured, which challenges the sensitivity 
of the assay, and the possibility of metabolism of the 
metabolite before excretion, so that the measured amount 
represents only a portion of the true level; co-elution of 
other metabolites which are indistinguishable from the 
products of interest is a further problem; the method is 
therefore not considered further here. 
There appears to be a general consensus that the most 
reliable assay procedures available are the chemilumines- 
cence-linked HPLC determination of lipid hydroperoxides 
(Yamamoto, 1994) and the HPLC-linked TBA measure- 
ment (Yamamoto, 1994). The isoprostane assay is gaining 
momentum and has been excellently reviewed recently 
(Morrow & Roberts, 1996). 
3.2.3. LDL oxidation. Particular techniques have been 
developed to determine the oxidation of LDL and a wide 
range of methods is now available (Esterbauer et al. 1992). 
A critical review of practical approaches to LDL oxidation 
has also appeared recently (Rice-Evans et al. 1996). 
The xylenol orange assay or FOX assay describes a 
sensitive spectrophotometric system for detecting authentic 
peroxides in LDL and has been successfully applied to the 
measurement of lipid hydroperoxides in LDL. Hydroper- 
oxides oxidize ferrous to ferric ions in dilute acid and the 
resultant ferric ions are determined using ferric sensitive 
dyes as an indirect measure of hydroperoxide concentration. 
Xylenol orange [o-cresolsulfonephthalein 3’3”-bis (methyl- 
imino) diacetic acid sodium salt) binds ferric ions with high 
selectivity to produce a coloured (blue-purple) complex 
with an extinction coefficient of 1.5 x 104/mol per cm and 
absorbance maximum of 560 nm. The method compares 
favourably with the iodometric assay, TBA assay and 
conjugated diene measurement. No extraction step is 
required for analysis of lipoprotein in the 900mV1 
methanol-25 m - H 2 S 0 4  environment in which the assay 
is performed. 
Triphenylphosphine is used as a specific reductant of 
hydroperoxides, converting them to the corresponding alco- 
hol. This allows the measurement of authentic hydroper- 
oxides reacting in the assay and removes any background 
signal generated. Each sample is therefore measured with 
and without triphenylphosphine, the difference between the 
two being the lipid hydroperoxides in the sample. Back- 
ground values for plasma have been reported to be high. The 
mean value obtained for native LDL is reported to be 13.3 
(SD 8.8) nmoVmg LDL (Rice-Evans et al. 1996). Lipid 
hydroperoxides can also be measured easily in LDL using 
the tri-iodide assay (El-Sadaani, 1989). The lipids of LDL 
are dispersed by the detergent used in an enzymic choles- 
terol assay kit and the hydroperoxides oxidize I- to 1, which 
is detected spectrophotometrically. The values given for 
native LDL for the iodometric method correspond to 
25 nmol/mg LDL protein (El-Sadaani, 1989), 18.6 (SD 
9.4)nmoVmg LDL protein (Esterbauer et al. 1992) and in 
the range of 10-20nmoYmg LDL protein (O’Leary et ul. 
1992). This sort of range was deemed to be at the borderline 
of the detection limit for the iodometric assay (Esterbauer et 
ul. 1992). 
The HPLC procedure for detecting lipid hydroperoxides 
has the advantage that the identity and mass of specific lipid 
peroxides may be determined down to very low concentra- 
tions, well below that available by the colorimetric methods. 
This sensitivity is dependent on the availability of chemi- 
luminescence detection (Kritharides et al. 1994; Stocker et 
al. 1991). It has recently been reported (Kritharides et al. 
1994) that LDL freshly isolated from healthy subjects was 
free from detectable amounts of cholesterol-ester hydroper- 
oxides and phospholipid hydroperoxides as measured by 
HPLC with post-column chemiluminescence detection, 
suggesting that if lipid hydroperoxides are present at all, 
the levels must be below 1 nmol/mg LDL protein. This 
method of detection does require considerable dedication of 
technical resources and is unlikely ever to be suitable for 
any routine assays in large-scale clinical research. In some 
cases, U.V. detection can be used but with lower sensitivity. 
A comment should be made on the wide-ranging differences 
between the detected endogenous peroxide levels in LDL 
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applying the HPLC-chemiluminescence method compared 
with the spectrophotometric assays. (A direct comparison of 
the methods has yet to be carried out in a single laboratory 
on the same LDL samples.) No one is sure whether the FOX 
and El-Sadaani (1989) methods are determining additional 
unidentified components (which might include protein 
hydroperoxides) or whether the HPLC assay is missing 
some contributing features. On the other hand, it may 
relate to the methods applied for isolating the LDL; for 
example, it has been reported that applying the FOX assay 
after rapid isolation procedures gives 3 nmoVmg LDL 
protein, compared with 13.3nmoVmg LDL using the 
sequential isolation methods (Kritharides et al. 1995). 
3.3. Oxidative damage to proteins 
Oxidative damage to proteins is of particular importance in 
vivo both in its own right (affecting the function of recep- 
tors, enzymes, transport proteins etc. and perhaps generating 
new antigens that provoke immune responses), and because 
it can contribute to secondary damage to other bio- 
molecules, e.g. inactivation of DNA repair enzymes and 
loss of fidelity of DNA polymerases in replicating DNA. 
The chemical reactions resulting from attack of ROS or 
RNS on proteins are complex. Free-radical attack can 
generate protein peroxides, which can decompose in com- 
plex ways (Ambe & Tappel, 1961; Fu et al. 1995). 
Most use has been made of the carbonyl assay, a general 
assay of oxidative protein damage (Levine et al. 1995) to 
assess steady-state protein damage in human tissues and 
body fluids. The carbonyl assay is based on the fact that 
amino acid residues in proteins (particularly histidine, 
arginine, lysine and proline) are particularly susceptible to 
attack by ROS producing carbonyl functions. Such 
increased carbonyl content can be measured after reaction 
with 2,4-dinitrophenylhydrazine. The carbonyl assay has 
become widely used and many laboratories have developed 
individual protocols for it (Levine et al. 1994, 1995). 
Sometimes the assay procedures used in a particular labora- 
tory are not precisely specified in published papers and even 
when they are, they often differ from those used originally 
by the group of Stadtman (Oliver et al. 1987; Levine et al. 
1994, 1995). This point is important because there is a 
considerable variation in the ‘baseline’ levels of protein 
carbonyls in certain tissues, depending on how the assay is 
performed (Cao & Cutler, 1995; Lyras et al. 1996). 
Contrariwise, broadly comparable values for protein carbo- 
nyls in human plasma, of < 1 nmoVmg protein have been 
reported by most groups, so plasma protein carbonyls should 
be a useful marker of oxidative protein damage for nutritional 
studies. More work needs to be done to identify the molecular 
nature of the carbonyls, namely, which amino acid residues 
have been damaged and in which proteins they reside. 
Westem-blotting assays based on the use of anti- 
dinitrophenylhydrazine antibodies have also been developed 
in an attempt to identify oxidatively-damaged proteins in 
tissues and body fluids (Keller et al. 1993; Levine et al. 
1994). A cautionary note is the covalent binding of certain 
aldehyde end-products of lipid peroxidation to proteins, gen- 
erating ‘carbonyls’ . Indeed, many oxidized molecules contain 
carbonyls which will interfere in the protein carbonyl assay. 
Several in vitro assays for damage to specific amino acid 
residues in proteins have been developed including assays 
of 3-hydroxy-~-tyrosine (L-DOPA) (produced by tyrosine 
hydroxylation) (Giseg et al. 1993), valine hydroxides 
derived from valine hydroperoxides (Giseg et al. 1993), 
ring-opening products of tryptophan oxidation (Griffiths et 
al. 1992; Maskos et al. 1992) 8-oxohistidine (Uchida & 
Kawakishi, 1993, 1994), dityrosine (Giulivi & Davies, 
1993) and ortho and meta-tyrosines, products of attachment 
of OH to phenylalanine (Karam et al. 1991; Wells-Knecht 
et al. 1993). The levels of any one (or, preferably, of more 
than one) of these products in proteins could, in principle, be 
used to assess the balance between oxidative protein 
damage and the repair or (more likely) hydrolytic removal 
of damaged proteins. The only products exploited to date 
have been the hydroxylated phenylalanines (Wells-Knecht 
et al. 1993). 
Attack of various RNS (ONOO-, NO; and possibly some 
other species) on tyrosine (both free and in proteins) leads to 
production of 3-nitrotyrosine, which can be measured 
immunologically or by HPLC or GC-MS techniques 
(reviewed by Wells-Knecht et al. 1993). Reduction of 
nitrotyrosine to aminotyrosine increases the sensitivity of 
measurement, since the latter compound can be measured 
using highly-sensitive electrochemical detection. Nitro- 
tyrosine is also excreted in human urine (Oshima et al. 
1990), although the possible confounding effect of dietary 
nitrotyrosine (if any) and of dietary nitrate and/or nitrite is 
yet to be evaluated. 
For measures of total ongoing protein damage, urinary 
nitrotyrosine (Oshima et al. 1990) might be useful as a 
generalized index of attack by RNS. Very little research has 
been carried out on the presence of oxidized amino acids 
and their metabolites in urine, except that bityrosine has 
been detected and can be measured by HPLC with fluores- 
cence detection. More work needs to be done in this area, 
and the possible confounding effects of oxidized proteins 
and amino acids in the diet (e.g. in irradiated foods; 
Halliwell & Chirico, 1993) must be considered. 
3.4. Measurement of antioxidant nutrients, carotenoids and 
jlavonoids extracted from humun plasma 
Several antioxidants are routinely measured in plasma: a- 
tocopherol (and y-tocopherol) whose antioxidant roles are 
well clarified in vivo; @-carotene, lycopene and other dietary 
carotenoids for which there is, as yet, little evidence of 
antioxidant activity in vivo; ascorbic acid, the most efficient 
reducing agent in vivo, its redox potential defining its central 
role as an aqueous phase antioxidant. There is, as yet, little 
information as to the importance of dietary flavonoids as 
antioxidants in vivo, nor evidence for such activity in vivo, 
although these polyphenols are highly efficacious free- 
radical scavengers in vitro. Furthermore, it is only recently 
that it has become possible to detect and identify flavonoids 
(and other glycosides) in human plasma, in non-supplemented 
subjects. 
Table 1 indicates the most favourable systems for detec- 
tion, identification and quantification of the antioxidants by 
HPLC. Plasma samples can be stored at -70”. 
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Table 1. The most favourable systems for detection, identification and quantitation of antioxidants by HPLC 
~ ~~ 
Antioxidant Method Conditions 
a-Tocopherol and y-tocopherol HPLC with fluorescence detection 
(bx296 brn340) 
Solvent system: hexane-methyl-t-butyl ether (92 : 8, vlv) 
Column: Novapak Silica 150 x 4.6 mm (4 pm) 
Internal standard: &tocopherol 
Carotenoids 
Flavonoids 
Detection limit: in plasma, 1.1 pmolll 
Solvent system: acetonitrile-methanol (90 : 10, v/v) 
Column: Supelco PKB 100, 5 pm 
or 
Solvent system: acetonitrile-methanol-dichloromethane- 
Column: Merck lichrocart man-fix, 5 pm 
Detection at: 455 nm (0-cryptoxanthin) 
HPLC with diode array detection 
hexane (gradient) 
468 nm (canthaxanthin) 
474 nm (lycopene) 
454 nm (0-carotene) 
Solvent system: 1 mlll HCI in 20% of aqueous 
Column: Nova-Pak C18 250 x 4.6 mm (4 pm) 
Internal standard: salicylic acid 
Detection: 280 nm (selective) 
HPLC with diode array detection 
methanol and acetonitrile (gradient) 
bX and )hm, excitation and emission wavelengths. 
3.5. Conclusions 
There is still a long way to go until validated, precise 
biomarkers of oxidative damage become routinely 
available. 
Concerning oxidative damage to DNA, both HPLC and 
GC-MS have their relative merits but also their limitations. 
Sight must not be lost of the potential for oxidative damage 
to DNA during its isolation from cells and tissues. 
Nevertheless, artifacts arising during derivatization are 
also problematical and HPLC with electrochemical detec- 
tion is one proposed route which circumvents the need for 
derivatization. Liquid chromatography-mass spectrometry 
techniques are also under development. An initiative by the 
British Ministry of Agriculture Fisheries and Food (MAW) 
is seeking to coordinate, within the MAW Antioxidants in 
Foods Research Programme, validation work at a number of 
centres within Europe, concerned with biomarkers of oxi- 
dative damage to DNA. The agenda seeks to have validated 
agreed biomarkers available for a new generation of human 
studies within 2-3 years. 
With regard to ex vivo markers of lipid oxidation in vivo, 
the measurement of circulating isoprostanes and lipid 
hydroperoxides is the best approach for plasma, the latter 
applying HPLC with chemiluminescence detection. Where 
this detection system is not available, the HPLC-TBA 
method has been shown to be an alternative, although 
lacking the high precision of the former. While the principle 
of isoprostane analysis is highly promising, this is still in its 
early infancy as there is a dearth of information in the peer- 
reviewed literature as yet, but it is rapidly gaining momen- 
tum. For urinary markers of lipid oxidation as an indicator 
of whole-body lipid peroxidation, the development of the 
isoprostane analytical techniques will be an important 
advance, since hydrocarbon gas exhalation has too many 
confounding variables to be applicable to studies on free- 
living human subjects. 
The potential for the application of methods for ex vivo 
detection of in vivo protein oxidation is promising. The 
outcome, of course, is the balance between damage and 
repair but to date very few products of oxidative damage to 
proteins have been exploited in this context. 
There is also a lot of excitement and activity in the areas 
of evidence for the formation of RNS in vivo. A major 
stumbling block here in the accumulation of evidence for 
oxidative damage in vivo is the confounding effects of the 
presence of oxidized proteins and amino acids in the diet. A 
lot more work needs to be done in this area. 
4. Nutritional options modulating oxidative damage and 
antioxidant defence systems 
4. I .  Introduction 
The body's antioxidant defence system is capable of being 
altered by dietary means. A first strategy to balance 
oxidative damage and antioxidant defence of human cells 
and tissues would be to enhance the antioxidant capacity by 
optimizing the dietary intake of antioxidants. A second 
approach may be to neutralize oxidative compounds in the 
diet. Crucial to these strategies is knowledge of the required 
level of relevant antioxidants in the diet to provide 
protective effects. Another prerequisite is accurate informa- 
tion about food sources, content and bioavailability of 
antioxidants. 
Epidemiological studies are necessary to quantify the 
impact of antioxidants on disease aetiology. Intervention 
trials formally test the efficacy of enhancing intake of 
antioxidants. In evaluating these health benefits preferably 
hard end-points (disease incidence, or recurrence and 
mortality) should be used. Alternatively intermediate end- 
points may be effective, provided that they are genuinely 
predictors of the disease of interest. In research on 
functional foods, the development and application of bio- 
markers is extremely important. In the causal pathway of 
disease occurrence one can distinguish biomarkers of 
exposure (dietary intake), biomarkers of biological response 
and of (subclinical) disease, and biomarkers of susceptibil- 
ity. For antioxidants, all types of markers have clear 
relevance. For example, blood levels of vitamin E (an 
Defence against reactive oxidative species S89 
exposure marker) may be studied in relation to oxidation 
resistance of LDL (a biological response marker) or to 
carotid artery wall thickness (a disease marker), in subjects 
with familial hypercholesterolaemia, or specific genotype 
(both susceptibility markers). Although biomarkers have the 
potential for improving validity and reducing bias, several 
problems are encountered. Biomarkers of exposure should 
accurately reflect relevant dietary intake or body status and 
early disease markers should have predictive value for the 
hard end-point. Since chronic diseases have long latency 
periods requiring large initial numbers to evaluate health 
effects, biomarkers of intermediate end-points may, in 
certain circumstances, legitimately be used more efficiently. 
An effective nutritional strategy will require knowledge 
of the type of antioxidants in the diet, their food sources, 
bioavailability and required levels of intake for protective 
effects. Protective effects of antioxidants have been found in 
mechanistic studies in vitro and in vivo, and epidemiological 
studies and certain intervention studies have provided useful 
information. However, it is appropriate to consider the 
totality of the evidence from basic science, epidemiology 
and intervention studies, rather than to rely on the evidence 
from any one type of study. 
4.2. Dietary antioxidants 
4.2.1. Sources of dietary antioxidants. There are both 
nutrient and non-nutrient antioxidants. Non-nutrient anti- 
oxidants include flavonoids (found for example in tea, red 
wine, onions, and apples), polyphenols and terpenes. The 
focus here will be on nutrient antioxidants, in particular 
vitamin C ,  vitamin E and carotenoids, although possible 
effects of non-nutrient antioxidants must be borne in mind 
in reaching complete understanding. Thus, it is important to 
ascertain whether non-nutrient antioxidants are genuinely 
bioavailable, in the particular sense of whether they are 
delivered under normal circumstances to tissues where they 
might be expected to be effective. Their activity as 
antioxidants themselves, or whether they participate in a 
cyclical fashion with other antioxidants, also remains to be 
established. 
The flavonoid content of beverages has been of great 
interest recently (Hertog et al. 1993). There is a large 
variation in the quercetin and myricetin content of red 
wines, which appears to depend on the type of grape and 
the vineyard of origin. Quercetin, kaempferol and myricetin 
are present in black and green teas, so that, together with 
fruit juices (mainly quercetin), these beverages can provide 
substantial amounts of flavonoids in the human diet. 
Vitamin C is found in citrus fruits, peppers, potatoes and 
other fruits and vegetables. The principal sources of vitamin 
E are vegetable oils and wheat germ. Other sources are nuts, 
seeds and leafy green vegetables. Of the over 600 caroten- 
oids, 0-carotene has been the most extensively studied. 
Good sources of 0-carotene are yellow or orange fruits 
and vegetables such as carrots, sweet potatoes, apricots, and 
mangoes, as well as dark green leafy vegetables such as 
spinach. There is now increasing interest in other major 
dietary carotenoids including lycopene (tomatoes), lutein 
(spinach, broccoli, maize), zeaxanthin (maize), a-carotene 
(carrots), and P-cryptoxanthin (citrus fruits). Chemical 
analysis of food products is steadily improving and until 
recently, there was a lack of reliable data for the food 
content of carotenoids other than &carotene. However, 
the recently released carotenoid food composition database 
of the US Department of Agriculture has included analysis 
of a-carotene, P-cryptoxanthin, lutein, zeaxanthin, and 
lycopene. A number of epidemiological studies of &car- 
otene and risk reduction of certain diseases are now being 
re-evaluated using information derived from this source on 
the other carotenoids. 
4.2.2. Antioxidant intake and status. Several cross- 
sectional surveys in a variety of population groups have 
been conducted. From these studies it can be concluded that 
according to the recommended daily allowances (RDA), the 
intake of antioxidants is adequate in healthy subjects. Lower 
levels have been observed in smokers, the elderly, and in 
patients with specific diseases or risk factors and several 
studies have demonstrated that intake of a number of 
antioxidants may be suboptimal in certain populations. In 
countries such as France and Italy antioxidant intake is 
largely adequate due to the abundant supply of fresh fruits 
and vegetables. However, in other countries where the 
selection of products is limited or more seasonal, a number 
of population groups are not able to meet the minimum 
requirements for vitamins E, C or 0-carotene. At particular 
risk are the less affluent and the elderly. 
The RDA, which are not established for carotenoids, are 
defined to prevent nutrient deficiencies and do not take into 
account the reduction in risk of chronic diseases. The levels 
of antioxidant nutrients that are effective in the reduction in 
risk of chronic diseases generally lie higher than the RDA. 
Since antioxidants may play important roles in the preven- 
tion of chronic diseases, the question is what would be the 
optimal range of intake to recommend. Lachance (1996) 
distinguishes the following categories: ‘experimental pro- 
tective intake’ ‘amount in optimal menus’, ‘desirable blood 
level’, ‘calculated intake necessary to achieve desirable 
blood levels’. For example, for vitamin E (current RDA: 
10 mg men, 8 mg women) the following values have been 
proposed: experimental protective intake > 23- 100 mg; 
amount in optimal menus 23mg; desirable blood level 
23 pmoV1; calculated intake necessary to achieve desirable 
blood levels 23 mg. For carotenoids the following values 
have been suggested: > 4 mg, 5.7 mg, 0.4 pmol/l, 3.2 mg 
respectively. Diplock (1 994) reviewed epidemiological 
studies of antioxidants and disease and suggested that the 
following daily intakes were associated with a reduced risk 
of cancer and cardiovascular disease; 150mg vitamin C ,  
40-60 mg vitamin E, and 9- 12 mg &carotene. Lachance 
(1996) has estimated optimal daily antioxidant intakes to be 
145 mg vitamin C ,  23 mg vitamin E, and 3.2 mg carotene. 
Biomarkers of antioxidant intake reflecting internal status 
(blood, adipose tissue, nails etc.) have been used success- 
fully but need much further development, and these also 
need to be non-invasive. Conceptually it is important to 
know the biological relevance and exposure timeframe of 
the biomarker. It is not only the dietary intake but other 
exogenous factors such as smoking and alcohol intake, and 
endogenous factors, that affect antioxidant status measured 
by a biomarker. For many bio-active compounds intake data 
are hard to get and, thus, more reliance will have to be 
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placed on biomarker data. It is thus imperative that the 
biomarkers that are used can be shown to be relevant to the 
outcome of the balance between oxidant and antioxidant in 
the majority of the population. 
Bioavailability of 
antioxidants depends on several food and host-related 
factors, as recently summarized by de Pee & West (1996) 
for carotenoids. A well-recognized food-related factor is 
the amount of antioxidant in a meal; for nutrients which are 
absorbed by a process of passive diffusion, the proportion 
of antioxidant absorbed decreases with increasing amounts 
in the food. The molecular forms of antioxidants in 
foods, for example, for which isomers or molecular 
linkages such as esters exist, are also important 
determinants of bioavailability. In addition, the food 
matrix in which antioxidants are located often influences 
availability of the nutrient. For example, &carotene is 
organized in a pigment-protein complex in green veget- 
ables, but found in lipid droplets in other vegetables and 
fruits. The 0-carotene can be released more readily, and is 
thus more biovailable, from a fat droplet than from a protein 
complex. 
Host-related factors influencing bioavailability include 
genetic factors, nutrient status and absorption modifiers. 
Absorption modifiers for fat-soluble vitamins and carotenoids, 
are lipids in the diet. To ensure efficient absorption, sufficient 
fat must be present in the meal and diet. 
A recent epidemiological study on lycopene intake and 
prostate cancer illustrates the importance of bioavailability 
in functional food research. Intake of tomatoes, tomato 
sauce, and pizza were significantly related to lower risk of 
prostate cancer. Tomato juice was not associated with a 
protective effect (Giovannucci et al. 1995). The lycopene 
from tomato juice has a low bioavailability, but cooking 
tomatoes in an oil-based medium substantially enhances 
intestinal absorption. 
Consumption 
of reduced-fat products in order to reduce energy intake, or 
of products with enhanced PUFA content (Sarkkinen et al. 
1993), may also affect the antioxidant status. It was shown 
that vitamin E intake was significantly lower among 
subjects who had an increased intake of reduced-fat 
products; however, no effect was observed for &carotene 
or lycopene, or for the antioxidant enzyme activities 
(superoxide dismutase, catalase and glutathione peroxidase) 
(Velthuis-te Wierik et al. 1996). There is, however, 
evidence that plasma antioxidant levels may not be a 
reliable index of body status; it was found that erythrocyte 
levels were unaffected in a study in men who had 
significantly lowered plasma levels of vitamin E (Haddad 
& Blankenship, 1985). Inhibitors of dietary fat absorption, 
which may be used to counteract obesity, appear to have fat- 
soluble vitamin-lowering properties (Melia et al. 1996). 
Besides a reduced antioxidant intake, fat substitutes like the 
sucrose polyester-based products may also reduce the 
absorption of fat-soluble antioxidants, although this only 
occurs when the fat intake is below 20% of total energy. 
However, published data do not suggest a major impact on 
the absorption of antioxidants when the level of inclusion of 
the fat substitute in the diet is low, such as would be the case 
when snack foods are prepared using the fat substitute. In 
4.2.3. Bioavailability of antioxidants. 
4.2.4. Fat intake and antioxidant status. 
general, diets low in PUFA do result in lower intake of 
vitamin E. On the other hand, PUFA-rich diets may affect 
the antioxidant-prooxidant balance requiring higher intake 
of antioxidants. 
4.3. Epidemiological studies on protective effects of 
antioxidants 
4.3.1. Cardiovascular disease. Several scientific reviews 
have addressed the role of antioxidants in cardiovascular 
disease (van Poppel et al. 1994). As discussed earlier, the 
primary role of antioxidants in reducing the risk of 
cardiovascular disease is through inhibition of peroxidation 
in LDL, although they may also influence other cardio- 
vascular disease processes. 
The epidemiological evidence for a protective role of 
antioxidants in cardiovascular disease is strongest for 
vitamin E. Three large-scale epidemiological studies 
demonstrated a relation between vitamin E intake and 
CHD. The Nurses Health Study, conducted in 87245 
women, found a significant 34% reduction in CHD in 
women who had consumed vitamin E supplements contain- 
ing more than 67 a-tocopherol equivalents (a-TE) daily for 
more than 2 years (for a definition of a-tocopherol equival- 
ents see p. S95). The Health Professionals Study of 39 910 
men showed vitamin E to be associated with a 41 % 
reduction in risk of CHD. Again, the greatest risk reduction 
was found with intakes of supplements of more than 67 a- 
TE for 2 years or more. 
Kushi et al. (1996) reported a significant 62 % reduction 
in mortality from CHD in women consuming foods contain- 
ing more than 6.46 a-TE/d. Surprisingly, there was no risk 
reduction seen with use of vitamin E supplements. This may 
be due to the lack of information on duration of supplement 
use, since from the other studies it appears that benefits of 
supplements are evident only after 2 years. 
Several epidemiological studies have examined the asso- 
ciation between vitamin C and cardiovascular disease. A 
European cross-cultural study found a significant inverse 
relationship between CHD mortality and serum vitamin C 
levels. The first National Health and Nutrition Examination 
Survey (NHANES I) results showed a 50% reduction in 
cardiovascular mortality associated with a daily consump- 
tion of greater than 50mg vitamin C. Gale et al. (1995) 
reported a significant protective effect against stroke of 
vitamin C intakes more than 45mg. However, neither the 
Nurses’ Health Study nor the Health Professionals Study 
described earlier found a significant protective effect of 
vitamin C. 
A recent study found that use of both vitamin E and C 
supplements was significantly more protective against car- 
diovascular mortality than use of vitamin E supplements 
alone, or no use of supplements (Losonczy et al. 1996). 
The epidemiological evidence for a role of carotenoids in 
cardiovascular disease prevention has been reviewed by 
Kohlmeier & Hastings (1995). A number of studies con- 
sistently showed a decreased risk of CHD among subjects 
with high P-carotene intake or serum levels. In the Massa- 
chusetts Health Care Panel study of 1299 elderly people, 
Gaziano et al. (1995) found a 75 % reduction in risk of fatal 
myocardial infarction in subjects in the highest quartile of 
Defence against reactive oxidative species S9 1 
carotene intake. A study of 25802 subjects showed a 
significant doubling of the risk of myocardial infarction in 
subjects with low serum 0-carotene levels (Street et al. 
1994). Several studies have, however, shown increased risk 
of CHD among subjects with low /3-carotene status. The risk 
seems to be confined to current smokers. However, 0- 
carotene intake contributes about 25 % of total carotenoid 
intake, thus carotenoids other than P-carotene as well as 
other components in fruits and vegetables may be 
responsible. The sparse data on individual carotenoids do 
not allow any firm conclusions. Several non-nutritive bio- 
active compounds may be of relevance in the aetiology of 
cardiovascular disease. Epidemiological studies on 
flavonoids are promising, but evidence of benefit is 
still fragmentary (Hertog, 1994; Muldoon & Kritchevsky, 
1996). 
Numerous epidemiological studies have 
shown that individuals who regularly consume fruits and 
vegetables have a decreased risk of cancer. A protective 
effect of fruit and vegetable consumption was found in 128 
of 156 dietary studies (Block et al. 1992). High intake of 
fruits and vegetables (in the upper one-fourth of the 
population) is associated with an approximately 50 % 
reduced risk of cancer, depending on the tumour site. The 
most consistent evidence of risk reduction associated with 
fruits and vegetables has been seen in the epithelial cancers 
of the respiratory and gastrointestinal tract (Steinmetz & 
Potter, 1991). Evidence is strong for lung cancer, with 
significant risk reduction found in twenty-four of twenty- 
five studies, as well as for stomach and pancreatic cancer 
with protection in twenty-six of thirty studies. For 
oesophageal, laryngeal and oral cancer, twenty-eight of 
twenty-nine studies showed a significantly reduced risk with 
fruit consumption. Cancers of the cervix, ovary and 
endometrium were associated with a significant risk 
reduction in eleven of thirteen studies. 
Although there is, therefore, indirect evidence that anti- 
oxidants (carotenoids, vitamin c ,  vitamin E and possibly 
non-nutritional antioxidants) may be beneficial (Taylor- 
Mayne, 1996), it has to be shown whether, and to what 
extent, this is true for individual antioxidants and which 
specific components are responsible. To illustrate the com- 
plexities: plasma 0-carotene in the normal physiological 
range is inversely related to lung cancer incidence. Other 
carotenoids such as a-carotene, which is strongly correlated 
with P-carotene, may however be the relevant factor. In 
addition, other bioactive components in fruits and veget- 
ables or other aspects of lifestyle, including diet, may play a 
causal role. Focusing, in epidemiological studies, on food 
items which mainly contribute to the daily intake of a 
specific bioactive compound, e.g. tomatoes and tomato 
products in the case of lycopene, may be a promising 
research strategy to identify the responsible factor. 
In attempts to identify the components in fruits and 
vegetables associated with risk reduction of cancer, epi- 
demiological studies focusing on intake or serum levels of 
specified antioxidants have been undertaken. In epidemio- 
logical studies of the protective effect of vitamin E on 
various cancer sites, vitamin E was associated with slightly 
reduced risk of lung cancer in studies involving low expo- 
sure to tobacco smoke. Several studies of oral, pharyngeal 
4.3.2. Cancer. 
and cervical cancer have also found a relationship between 
vitamin E status and cancer risk. The evidence for stomach 
and pancreatic cancers has not been consistent, and no 
association with breast cancer has been found. Diets high 
in vitamin E intake have been less consistently shown to be 
associated with cancer protection. Moreover, observational 
studies of vitamins C and E consumed in supplements 
provide little support for a strong protective role against 
cancer. 
As discussed earlier, vitamin C inhibits the formation of 
carcinogenic nitrosamines, stimulates the immune system, 
protects against chromosomal breakage, and regenerates 
vitamin E as part of the antioxidant defence system. The 
epidemiological evidence for a risk-reducing role of vitamin 
C in cancer is not as strong as for fruits and vegetables. 
However, an extremely strong and consistent protective 
effect of vitamin C was found in seventeen of nineteen 
studies of stomach, oesophageal, oral and pharyngeal can- 
cers (Block et al. 1992). Additional studies showed that 
subjects with low serum levels of vitamin C have a 50% 
increased risk of gastric metaplasia or chronic gastritis, 
which are both precancerous lesions. 
The most consistent body of epidemiological evidence 
showing protective effects of an antioxidant nutrient on 
cancer is for P-carotene. The strongest results are seen for 
lung cancer. Of twenty-five studies which investigated 0- 
carotene and lung cancer risk, twenty-four showed a signific- 
ant reduction in risk with high P-carotene intakes or plasma 
levels (van Poppel & Goldbohm, 1995). For stomach cancer, 
of fifteen studies, eight found a significant risk reduction 
associated with &carotene, and six showed a non-significant 
risk reduction. Only one study did not find a protective effect 
of @-carotene against stomach cancer. No consistent associa- 
tions were found with colorectal, prostate or breast cancer. 
Cataract and AMD 
are eye disorders which show increasing incidence among 
the elderly. Cataracts result from glycosidation of lens 
proteins initiated by U.V. light, which leads to opacification 
of the lens. It has been shown that in vitro lens proteins may 
be protected against oxidative attack by carotenoids and 
vitamins C and E. Of ten epidemiological studies, nine 
showed strong inverse relationships with at least one 
antioxidant nutrient. Observations are most consistent for 
vitamins C and E. 
Macular degeneration is the leading cause of irreversible 
blindness among persons older than 65 years. The caroten- 
oids lutein and zeaxanthin are present in the retina as 
pigments to protect against the damaging effects of light; 
strong inverse relationships were found between intakes of 
P-carotene, lutein and zeaxanthin and risk of AMD. Con- 
sumption of spinach, which is a good source of lutein and 
zeaxanthin, was also associated with significantly reduced 
risk of AMD. 
Free radicals have also been implicated in the develop- 
ment of neurodegenerative disorders such as Parkinson’s 
disease and Alzheimer’s disease, and in diabetes, rheumat- 
oid arthritis, and chronic obstructive pulmonary diseases. 
These age-related diseases may, therefore, be beneficially 
influenced by antioxidant consumption. However, as yet 
few epidemiological data exist on the association of anti- 
oxidants with these disease risks. 
4.3.3. Other age-related diseases. 
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The question whether it is a specific antioxidant or 
another component, or mixture, of fruits and vegetables 
that exerts the protective effect on disease cannot be 
definitively answered by epidemiological studies. Addi- 
tional information provided by intervention trials is 
needed before drawing any final conclusions. 
4.4. Human intervention studies of antioxidants 
The gold standard for testing the effectiveness of specific 
antioxidants is a randomized placebo-controlled 
intervention trial, preferably with a hard end-point such as 
disease occurrence or cause-specific mortality. Since trials 
conducted with clinical end-points of disease incidence or 
mortality are exceedingly costly and time consuming, 
intermediate end-points or validated biomarkers are increas- 
ingly being used. The limitations of intervention trials are 
that they can often only be interpreted for the particular 
study population, and for the antioxidant dose 
provided during the trial. Most of the intervention trials 
have focused on cardiovascular disease and cancer; only a 
few studies have addressed other age-related disorders, i.e. 
cataract. 
4.4. I. Cardiovascular disease. Intermediate end- 
points. A number of studies have supplemented 
individuals with antioxidants and measured the reduction 
in lipid peroxidation. However, indices of lipid peroxidation 
have not yet been definitively associated with cardio- 
vascular disease end-points. The only intervention studies 
which have evaluated the effect of antioxidants on 
cardiovascular disease using intermediate disease end- 
points have been with vitamin E. Using arterial narrowing 
as a marker for cardiovascular disease progression, the 
effect of vitamin E was evaluated in 100 patients 
randomized to 804 a-TE or placebo following angioplasty. 
The group receiving vitamin E showed significantly less 
recurrence of stenosis over the 4-month supplementation 
period. 
Carotid artery wall thickness, measured by non-invasive 
arterial wall imaging, has also been used as a reliable 
intermediate end-point for atherosclerosis. A recent study 
(Azen et al. 1996) demonstrated that use of vitamin E 
supplements larger than 67 a-TE/d reduced the progression 
of atherosclerosis. 
Although vitamin E shows promise 
in reducing cardiovascular disease, relatively few interven- 
tion trials have been conducted. The first of the trials to be 
reported was the a-tocopherol &carotene (ATBC) study 
which found no effect on cardiovascular disease mortality 
among heavy chronic smokers receiving 50mg vitamin E 
daily (Albanes et al. 1994). 
Linxian, China was the site of a study which gave a 
multivitamin-multimineral supplement plus 15 mg 0-carot- 
ene and found a 38% reduction in stroke incidence in 
subjects with oesophageal dysplasia. A non-significant 
10 % reduction in stroke incidence was also observed in a 
trial involving 35 000 subjects from the general population 
of Linxian who received 15 mg fi-carotene, 30 mg vitamin E 
and 50 kg Se (Blot et al. 1993). 
A trial conducted in 161 Japanese subjects, who con- 
sumed 3 or 100mg a-tocopherol/d for 6 years, showed a 
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significant reduction in the number of coronary disorders in 
the lOOmg/d group (Takamatsu et al. 1995). The recently 
published Cambridge Heart Antioxidant Study (CHAOS) 
found a significant reduction in the incidence of non-fatal 
myocardial infarctions in 2002 subjects randomized to 268 
or 536 a-TE/d (Stephens et al. 1996). However, there was a 
non-significant excess of cardiovascular deaths in the vita- 
min E-supplemented group. 
P-Carotene supplementation resulted in increased cardio- 
vascular disease incidence or mortality in two studies 
conducted in high-risk populations of smokers and asbes- 
tos-exposed workers, ATBC and the P-carotene and retinol 
efficacy trial (CARET) (Albanes et al. 1994; Omenn et al. 
1996). In a trial of healthy male US doctors, the Physicians’ 
Health Study (Hennekens et al. 1996) showed no effect on 
cardiovascular disease following 12 years of supplementa- 
tion with 50mg /3-carotene every second day. This was in 
contrast to earlier findings in a subgroup of the study which 
found a significant 50% reduction in secondary coronary 
events in subjects randomized to P-carotene (Gaziano et al. 
1995). 
It is known that in vitro vitamin C can regenerate vitamin 
E from the vitamin E radical which is formed during the 
inhibition of lipid peroxidation. Several large-scale trials are 
currently underway to study a combination of vitamins E 
and C, and &carotene, in the prevention, or amelioration, of 
risk of cardiovascular disease. 
4.4.2. Cancer. Intermediate end-points. Most of the 
intervention trials investigating the potential role of 
antioxidants in reducing the risk of cancer have focused 
on precancerous lesions. Relatively little work has been 
done on biomarkers for cancer, such as DNA damage. 
Recent reviews have summarized the use of antioxidants in 
oral leukoplakia, a precancerous lesion of the oral cavity 
(Kaugars et al. 1994; Garewal, 1995). Significant impact on 
lesion size or occurrence was found in seven intervention 
studies with a supplement of between 30 mg and 180 mg 0- 
carotene. @-Carotene has also been shown to reduce cervical 
as well as gastric dysplasia, and there are a number of 
intervention studies currently in progress. 
Several promising biomarker candidates for cancer have 
been suggested. Ideal characteristics of these biomarkers 
include: they should appear earlier than, or more frequently 
before, tumour development; they should be directly asso- 
ciated with tumour progression; they should be shown to be 
reversible; they should have inexpensive, accurate and 
simple methods of detection; they should be validated. 
Biomarkers of cellular proliferation and differentiation 
e.g. colonic adenomatous polyps and premalignant lesions 
such as dysplasia have been used to evaluate the preventive 
role of nutrient antioxidants. In contrast to observations 
using microscopic measures of cellular proliferation, the 
major antioxidants vitamins E and C, and p-carotene seem 
to be ineffective in decreasing the recurrence of colonic 
adenomas. Clarification is needed of changes in biomarkers 
that have been shown to occur with progression of 
proliferation, and in subsequent steps in the carcinogenic 
process, before definite conclusions can be drawn from 
these intermediate biomarker data. 
The preventive potential of antioxidants has been tested 
with intermediate end-points for other tumour sites, such as 
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lung, mouth, oral cavity and cervix. It is difficult to 
summarize the overall findings. However, until now, no 
really strong benefits have been identified. There is a need 
for a second generation of chemoprevention trials that 
include biomarkers, provided that these markers have 
fulfilled the criteria described earlier. 
Disease end-point. There have been a number of 
intervention trials which studied the potential for 0-carotene 
to reduce the risk of cancer. The 5-year Linxian trial of 
29584 adults in China found significant reductions in 
mortality from total and stomach cancer of 13 % and 21 % 
respectively, in the group randomized to 15 mg 0-carotene, 
30 mg vitamin E and 50 pg Se (Blot et al. 1993). In 3318 
adults with oesophageal dysplasia in the same community, 
there was a non-significant 8 %  decrease in oesophageal 
cancer in subjects randomized to a multivitamin, multi- 
mineral supplement with 15 mg 0-carotene. 
The Finnish ATBC study of 29133 chronic heavy 
smokers tested the effects of 20 mg &carotene, either 
alone or in combination with 333  a-TE for an average of 
6 years. There was a significant increase of lung cancer 
incidence (16 %) in the groups which received 0-carotene 
(ATBC Cancer Prevention Study Group, 1994). A more 
detailed analysis of the results revealed that the increased 
risk of lung cancer appeared to be restricted to participants 
who had smoked more than twenty cigarettes daily over an 
average period of 30 years (Albanes et al. 1996). 
The CARET study of 18 3 14 subjects at high risk of lung 
cancer (heavy smokers, and asbestos-exposed workers) 
evaluated the combination of 30 mg 0-carotene and 25 000 
IU vitamin A (equivalent to 7.5 mg retinol) over an average 
of 4 years. The intervention group had a significantly 
increased risk of lung cancer (relative risk 1.36; Omenn et 
al. 1996). A reduced risk of lung cancer (relative risk 0.80) 
was seen in subjects who were former smokers at the 
beginning of the study. Interestingly, participants with 
high initial serum @-carotene concentrations had a 31 % 
reduction in risk of lung cancer ( P  = 0.003), regardless of 
which group they were randomized to. This effect was also 
seen in the ATBC study and Physicians’ Health Study which 
was conducted over 12 years in 22 07 1 male physicians who 
consumed 50mg 0-carotene every second day. There was 
no beneficial influence of 0-carotene on cancer incidence. 
However, due to the long duration of the trial it is important 
to note that there were also no negative effects seen (Taylor- 
Mayne, 1996). 
4.5. Conclusions 
Epidemiological studies support the hypothesis that the 
antioxidants vitamin E, vitamin C and &carotene may 
play a beneficial role in reducing the risk of several chronic 
disorders. More research is needed on the impact of other 
non-nutrient compounds, such as other carotenoids and 
flavonoids, on human health. 
Human intervention trials testing the efficacy of anti- 
oxidants do not allow firm conclusions because of 
inconsistent findings, an insufficient number of studies and 
the use of varying doses. However, there is some evidence 
that large doses of &carotene may be deleterious to the 
health of heavy habitual smokers. 
In general, human intervention studies using hard end- 
points should be regarded as the gold standard. However, for 
diseases with a long induction period, such as cancer and 
cardiovascular disease, these types of studies may not be 
very feasible because of high costs, and intermediate end- 
points need to be sought to overcome this difficulty. The 
relationship between the disease and the nutritional factors 
that may have been involved at an early stage of its 
aetiology is, however, very complex and difficult to inter- 
pret. The development of biomarkers may, however, help in 
understanding the complexity of degenerative diseases at 
their different stages. 
5. Potential safety implications related to antioxidant 
nutritional enhancement 
5.1. Introduction 
The substances to be considered are the antioxidant nutri- 
ents vitamin C (ascorbic acid), vitamin E (a-tocopherol): 
the carotenoids (particularly 0-carotene): and the non-nutri- 
ent antioxidants, mainly flavonoids, which occur in food and 
which may be significant in the overall antioxidative pro- 
tection afforded by the diet. This benefit may be conferred in 
three main ways: (1) as antioxidants in food during storage 
and in the gastrointestinal tract; (2) as antioxidants in the 
human body in vivo; (3) by providing protection in food 
against oxidation as well as acting as true antioxidants in 
vivo. From the point of view of safety, the effect of 
antioxidants must strictly be concerned with their effects 
in vivo; however, the possibility that a given compound may 
be converted by chemical reaction, or bacterial action, into a 
toxic substance within the gastrointestinal tract, or during 
storage of the food that contains it, must also be borne in 
mind because such products may themselves be absorbed 
and exert their toxicity in vivo. 
5.2. Vitamin C 
The tolerance and safety of ingested vitamin C in human 
subjects has been reviewed several times (Hanck, 1982; 
Rivers, 1989; Diplock, 1995). In their review Bendich & 
Langseth (1995) consider in detail the fourteen controlled 
clinical studies that have reported no side-effects of vitamin 
C dosage, consistent with uncontrolled anecdotal reports 
which have appeared. In a more recent detailed review 
(Bendich, 1997), twenty-two placebo-controlled double- 
blind studies are reviewed that indicate no consistent 
detrimental side-effects of dosages of vitamin C up to 
daily doses of 6g. This conclusion is supported by the 
findings of a further eight less-well-controlled studies. The 
fact that very large numbers of people regularly take large 
doses of vitamin C without reports of any adverse effects is 
anecdotal support for the view that vitamin C is very safe 
and free from any adverse side-effects. It is clear that 
overload with vitamin C cannot occur in man even at very 
high levels of dietary intake (Rivers, 1989). Absorption, 
tissue concentration, metabolic pathways in which ascor- 
bate participates and renal elimination are all controlled by 
homeostatic mechanisms. The amount of a dose of vitamin 
C that is absorbed is inversely proportional to the size of the 
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dose and saturation was achieved at a K, of 5.44mM in a 
human study using intestinal perfusion. A consistent body 
pool size of ascorbate in man of about 20mgkg body 
weight, which appeared to change little irrespective of 
increases in intake to very high levels, has been reported 
(Kallner et al. 1979). However, a recent detailed study 
(Levine et al. 1996) provides more information; steady- 
state plasma concentrations were determined in normal 
subjects following administration of 30-2500 mg vitamin 
C daily. Steady-state plasma concentrations followed 
sigmoid kinetics, the steep portion of the curve occurring 
between 30 and 100 mg/d, and complete saturation did not 
occur until a daily intake of 1OOOmg. Different kinetics 
were obtained in blood cells. 
Possible adverse effects on human health have been 
reported from time to time. However, an exhaustive 
search of the literature has failed to find confirmation of 
this, and in each case evidence exists which refutes the 
finding which has led to the suggestion. This is summarized 
as follows. (1) The formation of urinary oxalate stones in 
subjects ingesting large amounts of vitamin C over a long 
period proved to be without foundation. Although human 
subjects do metabolize some ascorbate to C02, they excrete 
considerable amounts of unchanged ascorbate, and a range 
of metabolites among which is a small amount of oxalate; 
intake of ascorbate at levels in excess of the level required to 
maintain plasma levels at about 10 mgA results in excretion 
of the excess ascorbate unchanged (Kallner et al. 1979). 
Approximately 35-40 % of the daily excretion of oxalate is 
derived from ascorbate, but ingestion of large amounts of 
vitamin C results in a very small increase in the excretion of 
oxalate. It was shown clearly (Schmidt er al. 1981) that 
there is no dose-response relationship between adminis- 
tered vitamin C and excreted oxalate. Part of the explanation 
of the difference between this result and that of earlier 
workers is that in the early experiments the alkalinity of 
urine samples that arises on standing caused conversion of 
some ascorbate to oxalate; if steps are taken to avoid 
alkalinity then this conversion is minimal (Wandzilak et 
al. 1994). Recent work (Levine et al. 1996) indicates, 
however, that both oxalate and urate excretion are elevated 
beyond a daily intake of 1000 mg. (2) Similar anxieties were 
expressed with regard to urate excretion with the possibility 
that ascorbate might therefore indirectly exacerbate the 
effect of urate on gout. Two studies demonstrate that in 
healthy subjects ascorbate ingestion has no effect on the 
excretion of urate (Mitch et al. 1981; Schmidt et al. 1981). 
When high non-physiological plasma levels of ascorbate 
were induced by continuous infusion of ascorbate in gouty, 
as compared with normal, subjects (Berger et al. 1977), 
there was no effect on the clearance of urate indicating that 
it is highly improbable that high dietary intake of ascorbate 
has any effect on the urinary excretion of urate in subjects 
with gout. (3) Low plasma levels of vitamin BI2 were 
reported (Herbert & Hacob, 1974) to occur in subjects 
taking large doses of ascorbic acid but this was shown to 
be explained by analytical error. Erroneously low levels of 
plasma vitamin BI2 can occur if no cyanide is added to the 
assay to liberate protein-bound cobalamins and to stabilize 
the cobalamins so released (Newmark et al. 1976; Markus et 
al. 1980). (4) High ascorbic acid intake has been shown to 
have only a small effect on Fe absorption in healthy Fe- 
replete subjects (see review by Bendich, 1997) which 
repudiates suggestions that Fe overload could be a conse- 
quence of high ascorbate intake (Cook et al. 1984). It 
appears that the regulation of body Fe stores is unaffected 
by any increased availability of Fe from the diet that 
might be caused by an effect of the excess ascorbate on 
Fe. ( 5 )  Early reports (Cochrane, 1965; Rhead & Schrauzer, 
1971) of rebound scurvy in a small number of subjects 
following withdrawal of high vitamin C supplements were 
uncontrolled and have not been substantiated. Studies in 
guinea-pigs showed no evidence for these claims even when 
the study was designed to demonstrate a rebound effect. No 
increased catabolism of ascorbate was demonstrated during 
high vitamin C dosage nor was there any such increase when 
the vitamin C dosage was withdrawn (Norkus & Rosso, 
1975, 1981). Although the human data available remain 
contradictory, evidence available at present leads one to 
conclude that the phenomenon, if it exists at all, does not 
constitute a significant health problem. (6) Ascorbic acid 
added to cells in vitru in culture increases the rate of 
mutagenesis (for review see Rivers, 1989). Detailed reports 
exist of increased DNA fragmentation, increased DNA 
repair and chromosome aberrations in cells cultured in 
media that include added ascorbate. However, these effects 
only occur in cultures that contain added Cu2+ or Fe3+ ions 
and when steps were taken to ensure very low levels of these 
metals in the culture medium, no detrimental effect on DNA 
was observed. It can be concluded that in any such system in 
vitru the mutagenic effect of ascorbate is probably due to an 
ascorbate-metal ion-driven generation of 0-derived free 
radicals. There is no evidence of ascorbate-induced muta- 
genicity in vivu so that it is highly improbable that any effect 
that depends on metal ion-driven generation of free radicals 
caused by ascorbate has any significance. Efficient free- 
radical scavenging and repair systems protect DNA in vivu 
from such effects, and intracellular concentrations of ascor- 
bate, and concentrations of metals, which are efficiently 
sequestered on binding proteins, are so low as to be unlikely 
to be harmful (Halliwell & Gutteridge, 1989). 
The conclusion from an exhaustive survey of the 
literature is that oral intake of high (up to 600mg/d, i.e. 
six times the current RDA) levels of vitamin C are safe and 
entirely free from side-effects (Bendich, 1997). Very high 
levels (up to 2000 mg/d) have not been consistently reported 
to result in side-effects, although some reports of low 
reliability suggest that minor side-effects may occur. 
5.3. Vitamin E 
There have been four reliable reviews of the toxicological 
safety of oral intake of vitamin E (Bendich & Machlin, 
1988, 1993; Kappus & Diplock, 1992; Diplock, 1995). A 
problem in comparing studies of this nature has been the 
confusion that exists in the literature between different 
forms of vitamin E. In particular, IU are often quoted as a 
measure of quantity. The IU was abandoned by WHO in 
1957 (cited by Diplock, 1985) and studies which cite this 
measure are often ambiguous because it is not possible to 
determine the precise amount of vitamin E that was 
administered. 
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The international standard was based on 2-ambo-a-toco- 
pheryl acetate, which was an early sample of vitamin E 
which contained RRR-a-tocopheryl acetate with an 
unknown content of ‘2-epi-a-tocopheryl acetate’ (i.e. 
S,R,R-a-tocopheryl acetate). Because of the uncertainty as 
to the precise composition of this standard, the IU was 
abandoned, and in 1983 WHO recommended the use of 
precise descriptions of pure compounds. Despite this, the IU 
has continued to be used for labelling purposes, particularly 
in the US and Canada. There is no description of the various 
stereoisomers present, which may have widely differing 
biological activity, and this causes serious confusion. 
Vitamin E activity is expressed in the present paper as mg 
RRR-a-tocopherol equivalents (a-TE) wherever this is 
possible. To estimate the total a-TE the number of mg of 
tocopherols present is multiplied by a factor as follows: 
RRR-a-tocopherol x 1.0 
RRR-a-tocopheryl acetate x 0.9 1 
RRR-a-tocopheryl succinate x 0.8 1 
all rac-a-tocopherol x 0.74 
all rac-a-tocopheryl acetate x 0.67. 
Study of conventional aspects of the toxicity of vitamin E 
in animals was undertaken by many workers over a long 
period of time (Demole, 1939; Weissberger & Harris, 1943; 
Levander et al. 1973; Dysma & Park, 1975; Krasavage & 
Terhaar, 1977; Abdo et al. 1986). There is no evidence of 
any detrimental effect attributable to vitamin E, and similar 
conclusions are possible with respect to the teratogenicity 
and reproductive toxicity of vitamin E in animals at even 
large levels of intake of the vitamin (Hook et al. 1974; 
Krasavage & Terhaar, 1977). The possibility that vitamin E 
might have anticlastogenic and mutagenic effects has been 
studied extensively, and its potential mutagenicity was 
tested in several different ways (Shamberger et al. 1979; 
Beckman et al. 1982; Gebhart et al. 1985). Vitamin E was 
conclusively demonstrated to have no mutagenic properties, 
and indeed appears to have some effect in reversing the 
mutagenic effects of other compounds. Although early 
literature suggested that impure fractions containing 
vitamin E had tumour-promoting capability, there is a 
very large body of evidence that refutes this claim in studies 
where pure compounds were used (Yang & Desai, 1977; 
Weldon et al. 1983). Even at very high levels of inclusion in 
the feed (up to 25 000 IUkg feed), vitamin E was not shown 
to have any carcinogenic activity. 
Many reports purport to deal with the toxicity in human 
subjects of vitamin E, but there are different levels of 
reliability that can be attributed to them. Published reports 
include those that describe single observations on one 
subject, and planned toxicological studies which may or 
may not include placebo groups, but which often include 
bias because they lack blinding. There are fewer highly 
reliable studies which have been planned and carried out 
with all necessary rigour, which include sufficient numbers 
of subjects to enable proper statistical evaluation of the 
results; they use placebo groups and careful double-blind- 
ing, so that the results obtained are valid and reliable. 
Sufficient such studies have been undertaken to enable an 
authoritative view of the human toxicity, or lack of toxicity, 
of vitamin E. There are a few studies (Farrell & Bieri, 1975; 
Corrigan, 1982; Ernst & Matrai, 1985) which do not have 
adequate controls but are nevertheless of some interest. No 
consistent adverse effects of vitamin E emerge from these 
uncontrolled studies. However, the study of Corrigan (1982) 
indicates that vitamin E supplementation may aggravate 
vitamin K deficiency induced by warfarin anticoagulant 
therapy (see next paragraph). 
With regard to controlled double-blind studies of vitamin 
E toxicity in man, several reports show conclusively that 
vitamin E has very low toxicity in human subjects with no 
consistent adverse effects being reported in most subjects 
(Anderson & Reid, 1974; Gillian et al. 1977; Inagaki et al. 
1978; Tsai et al. 1978; Stampfer et al. 1983; Bierenbaum et 
al. 1985; Kitagawa & Mino, 1989). However, some adverse 
effects were observed on prothrombin time, or on other 
factors associated with blood clotting. This question was 
reviewed carefully (Kappus & Diplock, 1992; Diplock, 
1995); in several studies no effect was observed on blood 
clotting whereas in other studies there was a marked effect 
of vitamin E on some aspects of blood-clotting mechan- 
istics. Following a study of all the reports available it was 
concluded that vitamin E at a high level of intake may affect 
the coagulation variables if a low level of vitamin K is also 
present. Therefore, it is clear that vitamin E cannot be 
recommended for administration under these conditions. 
Vitamin E does not, by itself, cause coagulation abnormal- 
ities in persons who have no pre-existing coagulation 
abnormalities, and in individuals who are the majority of 
the population, vitamin E supplementation is entirely free 
from these adverse effects on blood-clotting. This view has 
been challenged recently (Kim & White, 1996). In a double- 
blind study in twenty-five patients given warfarin therapy, 
vitamin E (either 536 or 804 a-TE/d) was given for 4 weeks 
without any measurable effects on blood coagulation vari- 
ables. However, in view of the short time span of this study 
and the small number of subjects (four per experimental 
group) it would be unwise to overturn the consensus view 
that vitamin E therapy is contra-indicated in subjects with 
coagulation abnormalities. 
The question has been raised (Steinberg, 1993) of the 
safety of long-term ingestion of amounts of vitamin E in 
doses of 100mg/d which were found (Rimm et al. 1993; 
Stampfer et al. 1993) to confer significant protection against 
the risk of coronary artery disease. Higher doses than this 
(up to about 500mg vitamin E daily) have also been 
recently shown to confer benefit in apparently causing 
improvement in subjects with angiographically proven 
cardiovascular disease (Stephens et al. 1996). Results 
(Takamatsu et al. 1995) of a trial in which 100mg d-a- 
tocopheryl acetate was administered to human subjects for 6 
years indicate that there were no adverse effects of the 
treatment during clinical follow-up. In another study about 
250mg vitamin E was given daily for 5 years without any 
side-effects (Greenberg & The Polyp Prevention Study 
Group, 1994). While it is not possible at present to state 
categorically that oral ingestion of large amounts of vitamin 
E is entirely safe for long periods, because no one has been 
able to test the toxicity of the vitamin for very long periods 
of time, application to vitamin E of the usual criteria of 
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safety applied to any drug suggests that not only will long- 
term supplementation prove to be free from harmful side- 
effects but that this may also convey considerable health 
benefit. 
The following conclusions, which were reached earlier 
(Kappus & Diplock, 1992; Diplock, 1995) with respect to 
the safety of oral intake of vitamin E by human subjects, can 
be endorsed here. (1) The toxicity of vitamin E is very low. 
(2) Animal studies show that vitamin E is not mutagenic, 
carcinogenic or teratogenic. (3) Reported increases in serum 
lipids in human subjects following high oral dosage are 
inconsistent and of little significance. (4) In double-blind 
human studies, oral dosage resulted in few side-effects, even 
at a dosage as high as 3.2 g/d. (5) Dosage up to 1000 mg/d is 
considered to be entirely safe and without side-effects. (6) 
Oral intake of high levels of vitamin E can exacerbate the 
blood coagulation defect of vitamin K deficiency: high 
vitamin E intake is contra-indicated in these subjects. 
5.4. Carotenoids 
Present knowledge of the human toxicology of carotenoids 
derives almost exclusively from work on @-carotene; the 
assumption that other carotenoids have similar toxicology to 
@-carotene may not be justified. For instance the absorption, 
uptake and tissue distribution may differ among the differ- 
ent carotenoids, some of which are bioavailable and others 
of which are not. Reviews about the safety of @-carotene 
(Bendich, 1988; Diplock, 1995) are supported by a review 
(Wang, 1994) on its absorption and metabolism. Use of @- 
carotene as a food and cosmetic colourant and as a drug and 
nutrient has necessitated extensive reliable toxicity studies 
done using a range of techniques (Bagdon et al. 1960; 
Heywood et al. 1985). The Ames test revealed no muta- 
genicity, which was confirmed by studies using the mouse 
bone-marrow micronucleus test. Embryotoxicity was not 
found in rats and rabbits, and in a multiple-generation study 
in rats given up to 1 g/kg per d orally, reproductive function 
was normal, and there was no interference with embryonic 
morphology. A study conducted over a 2-year period in 
dogs revealed no tumourigenicity or chronic toxicity of any 
kind and in a mouse carcinogenicity study @-carotene was 
without any tumourigenicity. In several organs of dogs and 
mice given high doses of @-carotene vacuolated cells were 
seen due to the formation of fat storage cells; this was not 
dose-related and was thought to be harmless. These toxicity 
trials led to @-carotene being placed in the US Food and 
Drug Administration category of ‘foods generally recognized 
as safe’ for use as a food colourant, in drugs and cosmetics 
and as a dietary supplement and nutrient (Office of Life 
Sciences Research, 1979). In addition @-carotene has been 
used for 30 years to treat patients with genetically inherited 
photosensitivities; in this context the ingestion of large 
amounts of pure @-carotene has not produced toxic side- 
effects (Matthews-Roth, 1986). Some individuals taking 
supplements of > 30 mg/d may experience hypercarotenae- 
mia but this disappears quickly after discontinuing the 
treatment, and it is a benign condition without permanent 
adverse effects. Anecdotal reports, linked to @-carotene, of 
leukopaenia, reproductive disorders, increased prostatic 
cancer incidence, retinopathy, and allergic reactions have 
not been substantiated in proper clinical trials. A short-term 
phase I toxicity trial of supplemental @-carotene in a small 
number of human volunteers (Xu et al. 1992) demonstrated 
a progressive statistically significant decrease in serum 
vitamin E concentration during supplementation for 9 
months with 15, 30, 45 and 60mg 6-caroteneld. However, 
other studies have demonstrated no such interaction (Willett 
et al. 1983; Albanes et al. 1992; McLarty, 1992; Goodman 
et al. 1994; Nierenberg et al. 1994; Ribaya-Mercado et al. 
1995). There is no satisfactory explanation available for the 
results of Xu et al. (1992), but the balance of probability is 
that there is no likelihood of any interaction between @- 
carotene and a-tocopherol that would alter the nutritional 
availability of vitamin E to human subjects. Careful 
monitoring of nutrient interactions should become part of 
all long-term intervention studies. 
It can be concluded that supplementation of normal 
individuals in the population with moderate amounts of @- 
carotene can be undertaken safely. The safety of this 
practice by heavy smokers, who are at high risk of devel- 
oping lung cancer, has been put in question by two recent 
studies (ATBC Cancer Prevention Study Group, 1994; 
Omenn et al. 1996), details of which are given in section 
4. The increase in incidence of lung cancer (18 % and 28 % 
respectively in the two studies) has no easy explanation. 
Both studies were conducted among subjects who had a high 
risk of developing lung cancer and may have been at an 
advanced precancerous state when the @-carotene adminis- 
tration was commenced. Observational epidemiological 
evidence suggests that subjects who are not in this state 
may benefit from @-carotene administration which is likely 
to exert a protective role at an early stage of the cancer 
process. Until further work clarifies the situation in heavy 
smokers with respect to taking supplements, larger doses 
should be avoided by such individuals. However, it should 
be stressed that for normal subjects who do not smoke, @- 
carotene supplementation is entirely safe. 
5.5. Non-nutrient antioxidants (javonoids and other related 
compounds) 
Few data exist on absorption, metabolism and possible 
adverse effect of flavonoids and flavonoid-related com- 
pounds, such as genistein, daidzein or phenolic acids. 
Since these compounds are present in our daily diet they 
are believed to carry no health problems. Obviously, reliable 
comprehensive safety data, practically non-existent today, 
will be required, should it appear that increased intakes of 
specific flavonoids and other phenolic compounds would 
confer significant health benefits. As concentrations of 
phenolic compounds in edible plants, fruits and vegetables 
vary considerably, estimates of human daily intakes range 
from approximately 100 mg to 1000 mg (Kuhnau, 1976), 
depending on the diet. 
5.5.1. Absorption. It appears that two major metabolic 
routes operate in man in the absorption of dietary 
flavonoids. Intestinal micro-organisms hydrolyse the 
flavonoid glycosides (nearly all the flavonoids are present 
as glycosides) to their constituent aglycone and sugar. Most 
of the aglycones are subsequently metabolized by micro- 
organisms. A minor portion is absorbed as aglycones 
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(Hackett, 1986). A study on the absorption of quercetin in 
volunteers found no detectable amount of quercetin or of its 
metabolites in plasma or in urine (Gugler et al. 1975). 
In a more recent study less than 0.25% of ingested 
quercetin was found to be excreted, either unchanged or 
as conjugates, in the urine of healthy ileostom volunteers 
(Hollman et al. 1995). In contrast, 0.1-1.4% C-labelled 
catechin was excreted in urine in the form of unchanged 
compound. However, 5 5 %  of the ingested dose was 
excreted as its methylated derivatives (Hackett et al. 
1983). There appear to be no human studies available on 
the absorption and metabolism of anthocyanins. 
When tested in vitro in 
cell cultures, flavonols and especially quercetin have a high 
cytotoxicity (Babich et al. 1993). However, their toxicity in 
vivo was shown to be remarkably low when tested in rats 
(National Toxicological Program, 1992). Most of the 
flavonols including quercetin are also mutagenic in the 
Ames test and other short-term tests in vitro (Sugimura et al. 
1977; International Agency for Research on Cancer, 1983). 
However, other tests in vitro have shown quercetin to be a 
potent inhibitor of mutagenic activity of food carcinogens, 
such as heterocyclic aromatic amines (Stavric et al. 1990). 
The same anti-mutagenic activity was found in the livers of 
mice when quercetin was added to their feed (Stavric, 1994; 
Stavric et al. 1990). Another test on mice showed the 
mutagenic effect of heterocylic aromatic amines to be 
enhanced by quercetin (Rowland, 1993). 
Studies on three flavonols, quercetin, myricetin and 
kaempferol carried out by the molecular toxicology 
branch of the US Food and Drug Administration point to 
the prooxidant properties of these compounds and ‘suggest a 
dual role for these flavonoids in mutagenesis and 
carcinogenesis’ . The authors stress that these polyphenolic 
flavonoids are generally considered to be both antioxidants 
and anticarcinogens (Sahu, 1992; Sahu & Gray, 1993, 
1994); these studies were performed in isolated rat liver 
nuclei under aerobic conditions. 
A study on quercetin conducted by the US National 
Toxicological Program (1 992) concluded that there was 
‘some evidence of carcinogenic activity’ in male rats 
receiving 40 000 mg quercetinkg diet for 2 years; there 
was no evidence of carcinogenicity in the lower dose 
groups. It is important to note that the statistical evaluation 
of the National Toxicological Program study was not 
without controversy (Ito, 1992) and a number of previous 
long-term, well-controlled feeding experiments with rats, 
mice and hamsters did not show any carcinogenic activity of 
quercetin (Hirono et al. 1981; Ito et al. 1989). It should also 
be emphasized that quercetin is one of the most abundant 
flavonoids, being present in most common vegetables and 
fruits with an average daily intake estimated to be approx- 
imately 25 mg/person (National Toxicological Program, 
1992). The consumption of quercetin from a regular diet 
appears not to induce health problems. The observed very 
low bioavailability of quercetin in human subjects may 
explain the apparent contradiction between the results of 
the tests carried out in vitro and its apparent beneficial 
effects in man, although the available evidence for bene- 
ficial effects of quercetin needs further confirmation. 
Whereas flavonoids are not mutagenic, anthocyanins have 
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5.5.2. Possible adverse effects. 
not been tested regarding their potential mutagenic proper- 
ties. No carcinogenic effects have been reported for other 
flavonoids. 
Tannins, which may exert anticarcinogenic effects by 
acting as free-radical scavengers, have also been reported to 
be associated with an increased incidence of oesophageal 
cancer (Mortin, 1989), but there is no definite evidence to 
support this assertion. The acute toxicity of tannins was 
studied in rats, mice and rabbits. Median lethal dose (LDSo) 
values for a single dose of orally administered tannins range 
from 2.25 to 6.OOgkg body weight (Singleton & Kratzer, 
1989). These results are difficult to apply to the human diet 
since in food the chemical structures and the molecular 
masses of tannins vary considerably. Anthocyanin extracts 
are already widely used by the food industry. Anthocyanins 
obtained by extraction of vegetables and edible fruits have 
been approved worldwide as food colours (see, for Europe, 
European Parliament and Council Directive, 1994). They 
are most commonly based on the following anthocyanidins: 
peonidin, malvidin, delphinidin, petunidin, pelargonidin, 
cyanidin. There are two reviews (World Health Organiza- 
tion, 1982; Timberlake, 1988) of the limited toxicological 
data concerning anthocyanidins. These include data on 
mutagenicity, reproductive toxicity, and teratogenicity and 
conclude that anthocyanin-containing extracts are of a very 
low order of toxicity. The only negative effects were 
reduced organ and body weights associated with reduced 
energy intakes at the highest dose, probably reflecting 
reduced palatability (Clifford, 1996). An average daily 
intake of 2.5mgkg body weight per d was allocated for 
anthocyanin colour from grape skin extracts (World Health 
Organization, 1982), the composition of which may vary 
depending on grape variety and extraction process. Antho- 
cyanin colours from grape skin extracts also contain other 
flavonoids and some tannins. Recently epigallocatechin 
gallate and green-tea extract have been shown to prevent 
gastrointestinal carcinogenesis in volunteers; no adverse 
effects were reported (Yamana et al. 1996). 
In conclusion, it is not possible to provide a definitive 
statement as to the toxicity of flavonoids and other non- 
nutrient antioxidants, because the literature is either 
controversial or lacking. A key question that needs to be 
resolved is the uptake and tissue distribution of non-nutrient 
substances, which has been hampered by the lack of suitable 
methodology. Recently a reliable and reproducible method 
has been published which shows that flavonoids are indeed 
absorbed in human subjects and enables the measurement in 
human plasma of flavonoids as their glycosides at concen- 
trations of 05-1.6 mmol/l (Paganga & Rice-Evans, 1997). 
It seems advisable therefore to test rigorously well-defined 
flavonoids in toxicological programmes for possible adverse 
effects if new scientific evidence confirms potential 
beneficial effects on human health. 
6. Role of food technology in nutritional and safety 
aspects of antioxidants 
6.1. Introduction 
Our food supply is safer and offers more variety today than 
it ever has in the past and this can be largely attributed to the 
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applications of food technology to food raw materials. Food 
processing preserves foods safely so that they can maintain 
high nutritional and organoleptic values during storage and 
achieve a wide distribution. 
After microbial spoilage, oxidation is the second most 
important cause of food spoilage, even in those products 
which might be considered low in oxidizable substrates, 
such as potato flakes. Important nutrients such as unsat- 
urated lipids, vitamins and proteins can be lost through 
oxidation. This has been known for a long time and there- 
fore attention to the control of oxidative processes in foods 
has been one of the highest priorities of the food industry. 
Until recently antioxidants have been viewed as tools in this 
fight against oxidation but now, because of growing recog- 
nition that antioxidants are themselves important for the 
maintenance and optimization of health, special efforts may 
be required to protect the antioxidant nutritional value of 
food. 
O2 is the enemy of antioxidants. This is evident but bears 
mentioning because the protection of foods from interaction 
with O2 is the basic principle on which antioxidant 
protective technologies are based. Many of these have 
been drawn from experience with lipid oxidation. These 
technologies can be conveniently broken down into two 
sections: physical and chemical. 
6.2. Physical processes 
6.2. I. Structural integrity. The structural integrity of the 
food plays an important role in protecting antioxidants from 
contact with O2 and thus potential oxidative destruction. In 
its whole food form, the antioxidant is encased in its 
protective liposome or cell membrane structures and is out 
of contact with both O2 and oxygenases. For example, intact 
oilseeds are quite stable but once they are crushed, extracted 
and heated in the refining process, resistance of the oils to 
oxidation decreases. Thus, one nutritional consequence of 
this loss of structural integrity is negative in that some 
antioxidants are lost to oxidation. However, the positive 
nutritional consequence is that antioxidants become more 
bioavailable. 
It has been known for some time that in human subjects 
the gastrointestinal absorption of carotenoids from veget- 
ables is inversely proportional to particle size (Rodriguez & 
Irwin, 1972). Heat treatment also improves absorption: 
more lycopene appeared in plasma when human subjects 
drank heated tomato juice compared with the same dose of 
raw tomato juice (Stahl & Sies, 1992). In another recent 
study, ascorbic acid was more bioavailable from cooked 
broccoli than it was from the raw form (Mangels et al. 
1993~).  This appears to be a human attribute: studies in 
other species such as rats (Sweeney & Marsh, 1974) and 
preruminant cows (Poor et al. 1993) have shown, 
respectively, no differences or only small differences in 
absorbability of cooked v. uncooked vegetables. Therefore 
it may not be appropriate to extrapolate information 
obtained using animal models to man. 
The moisture content of foods 
should be judiciously chosen and carefully controlled if the 
antioxidant content of the food is to be optimized since 
oxidation shows a U-shaped curve, i.e. rapid rates of 
6.2.2. Moisture content. 
oxidation when moisture content is low as well as when it 
becomes too high. Most dehydration processing will destroy 
lipoxidases but if water content falls below a level which 
permits the formation of a protective monolayer of water 
over the surface of the food increased auto-oxidation can 
result (Labuza, 1971). 
According to Labuza (1971), a higher level of water can 
act as a solvent which mobilizes catalysts and reactants to 
sites of oxidation. Water may also interact chemically or by 
H-bonding with other molecular species. 
Thermal treatment holds an import- 
ant place in food processing because of the many benefits it 
brings to food preservation. It also has both a negative and a 
positive impact on antioxidants. The positive effects include 
inactivation of oxidases, and breakdown of food structures 
leading to improved bioavailability. These topics have been 
dealt with earlier. 
Degradation. Thermal treatment also has an important 
negative impact on antioxidants in foods. Carotenoids and 
anthocyanins are sensitive to heating: in many studies of 
foods and food models, these compounds progressively 
degrade as time and temperature increase. With radical 
treatments this effect can be radical too. For example at 100" 
for 5 min, only 0-93 % 0-carotene was lost in a glycerol 
model, but 97.8 % was lost when the thermal treatment was 
carried on for 4 h  at 210" (Onyewu, 1985). In palm oil 
thermal destruction of &carotene doubles with every 20" 
rise in processing temperature (Jideani, 1992). However, 
technologies exist to protect 0-carotene, tocopherols and 
tocotrienols. Using a modification of the refining method 
one Malaysian supplier guarantees specifications of 400 mg 
0-carotenekg and 800 mgkg minimum of total tocopherols 
and tocotrienols. This is quite a good level given that most 
crude palm oils contain on average only 500-750mgkg 
(Hood, 1995). Water-soluble antioxidants such as ascorbic 
acid are also sensitive to heating. Blanching of green beans, 
spinach, broccoli, or peas before freezing resulted in, 
respectively, losses of 0, 20, 20 and 33 % of this vitamin 
(Unilever, 1995). 
Isomerization. Another effect of heating is to increase 
isomerization of carotenoids in foods. In one study, thermal 
processing of guava juice increased cis-lycopene levels by 
5-fold and decreased trans-lycopene, although in this food, 
&carotene remained unchanged (Padula & Rodriguez, 
1987). Supplemental 0-carotene added to wholewheat 
breads and crackers before baking showed significant 
trans to cis isomerization (4-15 % for bread and 18-23 % 
for crackers) (Ranhota et al. 1995). More isomerization was 
observed in the crackers because of the more severe thermal 
treatment, and less water was left in the final product 
compared with the bread product. The processing associated 
with canning is sufficient to cause isomerization of caroten- 
oids: 18-30 % of 0-carotene is converted to cis isomers by 
usual treatment of typical fruits and vegetables (Quackenbush, 
1987). The nutritional significance of this is that the cis isomer 
of 0-carotene is markedly less well absorbed by the 
gastrointestinal tract and markedly less well transported in 
the body (Gaziano et al. 1995). Thus, cis and trans isomers 
of carotenoids are not biologically equivalent. 
Losses of antioxidants from fresh 
fruits and vegetables during storage can be quite significant. 
6.2.3. Temperature. 
Storage temperature. 
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At ambient temperature 90% of vitamin C was lost from 
spinach leaves within 3 d. At refrigerator temperatures this 
loss was greater than 50%. In one recent study, freezing 
effectively halted any decrease in vitamin C losses in peas, 
broccoli, green beans and spinach over 3 months (Unilever, 
1995). 
There are some processes 
which can eliminate or minimize the presence of O2 in the 
foods. This is quite important as, for example, the rate of 
degradation of L-ascorbic acid in orange juice (Kennedy et 
nl. 1992) and in canned, sterilized green beans (Bloeck et al. 
1986) depends on O2 present in the sample. Fruit juices 
containing entrapped air are deaerated by being sprayed 
into a vacuum deaerator which minimizes the potential 
for destructive changes to ascorbic acid and other oxidizable 
components due to 02. Other products e.g. dried red 
peppers (Lee et al. 1992) can be prepared or packaged 
under a N2 atmosphere with successful retention of 
antioxidants. 
One of the newer approaches is the potential to use 
enzymes as antioxidative agents in food systems. Enzymes 
can act by removing 02, ROS such as H202 and superoxide 
radicals or by reducing lipid hydroperoxides. The enzymes 
presently under most study are glucose oxidase (EC 
1.1.3.4), thiol oxidase, galactose oxidase (EC 1.1.3.9), 
pyranose oxidase and hexose oxidase in conjunction with 
catalase, superoxide dismutase and glutathione transferase 
and glutathione peroxidase (for review see Meyer & 
Isaksen, 1995). These systems are under study but are 
not currently of commercial significance in the food 
industry. 
At wavelengths of less than 
500 nm, light is an important generator of lipid oxidation 
and vitamin destruction. Improving packaging by adding 
colour (red, brown, black) or obscuring material is one of 
the most effective strategies for protecting foods from light. 
Some components of foods act as photosensitizers: 
riboflavin, chlorophyll, myoglobin, haemoglobin pigment, 
pheophytin and certain conjugated double-bond systems are 
examples. Sandmeier (1996) has recently shown that 
curcumin and curcumoid compounds, which are often 
present in curry mixes, have rather potent photosensitizing 
properties. Removing these photosensitizers or incorporat- 
ing food-grade quenchers such as &carotene, and a -  
tocopherol, together with chelators of trace metals, can 
also be effective means of controlling the damaging effects 
of light. 
The effects of irradiation are some- 
what variable depending on the food being irradiated, the 
nutrient under study and the strength and length of time of 
irradiation. The irradiation of peppers demonstrated no 
change in vitamin C content in doses up to 300 Gy (Mitchell 
et al. 1992). In fact, post-irradiation storage resulted in 
increases in total vitamin C in intact fruits and vegetables 
(Mitchell et al. 1992). 
In one study of chicken meat, p- and a-tocopherol 
decreased linearly with irradiation in direct relationship to 
dose. At 3 kGy, which is the maximum recommended by the 
Food and Drug Administration for chicken, 15 % p-tocopherol 
and 30 % a-tocopherol were lost (Lakritz & Thayer, 1992). 
However, a newer study by the same authors (Lakritz & 
6.2.4. Minimizing oxygen. 
6.2.5. Protection from light. 
6.2.6. Irradiation. 
Thayer, 1994) showed different results: only a 6 % reduction 
in a-tocopherol and no significant change for &tocopherol 
in chicken meat at 3 kGy and 2". Irradiation with a low dose 
(0.010 kGy) had no effect on the polyphenol content of herb 
teas (Katusin et al. 1988). 
6.3. Chemical processes 
6.3.1. Enzymes. The control of polyphenol oxidases has 
been a priority in food science for a long time because 
oxidized polyphenols are responsible for undesirable brown 
colours in cut fruits and vegetables, and for the development 
of off-colours and off-flavours in frozen foods over time. 
Inactivation of these enzymes can be achieved by rapid 
high-temperature heat treatment (blanching) while the fresh 
character of the food can still be retained. Rapid inactivation 
of the oxidases after pressing apples is a prerequisite for the 
long-term stability of apple juice (Anonymous, 1993). 
Extrusion processes, because of their conditions of high 
temperature and pressure, destroy oxidases and increase 
lipid binding to protein and carbohydrate elements in the 
food which acts to protect from lipid oxidation (Artz et al. 
1992). 
Cloudy fruit juices are more stable than clear juices 
because of their content of polyphenols and their glycosides. 
These latter compounds are not substrates for polyphenol 
oxidase (EC 1.10.3.1) (Baruah & Swain, 1959). For the 
preparation of clear juices such as apple or raspberry, 
pectinases are often used. These enzymes hydrolyse the 
glycosidic side-chains of flavonoids which are then less 
oxidatively stable in the juice (Rommel & Wrolstad, 
1993a,b). However, glycosides of flavonols and isoflavones 
are poorly absorbed by the small intestine compared with 
their aglycones (Brown, 1988). Therefore the nutritional 
impact of using pectinases is difficult to gauge: on the one 
hand the polyphenols become more bioavailable, and there- 
fore potentially capable of having an impact on health, but 
on the other hand there may be fewer of them in the food, as 
being less stable, they are oxidized. 
6.3.2. Supplementation. Supplemental antioxidant 
nutrients can be added to foods for technological reasons. 
Ascorbic acid is widely used to increase the resistance to 
oxidation of many foods. For example, it is used as a dip for 
cut fruit and vegetables as it is preferentially oxidized 
instead of the catechol-tannin compounds and effectively 
inhibits enzymic browning reactions (Potter & Hotchkiss, 
1995). In hydrophobic food matrices, vitamin E is also 
frequently used to provide antioxidant protection. Since 
vitamin C recycles vitamin E, it is desirable to use both of 
these antioxidants together. However, since vitamin C is 
hydrophilic and vitamin E lipophilic, it is difficult to use 
them together effectively in food systems. One of the 
solutions is to use ascorbyl palmitate, a hydrophobic 
vitamin C which has been shown to be useful in food lipid 
systems (Klaui & Pongracz, 1981). 
A mixture of vitamin E, vitamin C and phospholipids is 
an effective antioxidant partly because the phospholipid acts 
as an emulsifier, allowing the two vitamins to be in contact 
with one another and also because the phospholipid itself 
actively participates in the antioxidant process (Loeliger et 
al. 1996). Both vitamins can be incorporated into liposomes 
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which can be used as a delivery system in oil-in-water 
emulsions (Pothakamury & Barbaosa-Canovas, 1995). 
Sometimes higher levels of antioxidants can be incorporated 
indirectly into a foodstuff. Feeding chickens supplemental 
vitamin E increased a-tocopherol levels in the meat and this 
was associated with greater stability (less formation of 
volatiles) of the meat when it was later irradiated (Patterson 
& Stevenson, 1995). 
Supplementation with nutrient antioxidants is, thus, a 
reasonable strategy in many situations for the improvement 
of the stability and nutritional value of a processed food. 
Indiscriminate supplementation with antioxidants, as with 
any nutrient, would however be quite undesirable as there 
are many unknown factors concerning potential inter- 
relationships in vivo between different antioxidants and 
eventual long-term effects. To illustrate this point, in a 
recent study, 0-carotene doses resulted in less lycopene in 
LDL suggesting that the two related hydrocarbons compete 
for a similar absorption or transport mechanism (Gaziano et 
al. 1995). 
Non-nutrient antioxidants such as SO2 can be used to 
advantage to protect those with known or suspected nutri- 
tional benefit. For example, the phenolic and procyanidin 
composition of grape juice processed with SO2 is 
consistently higher than that of grape juice processed with- 
out SO2 addition (Spanos & Wrolstad, 1990), although there 
appears to be no effect on quercetin. SO2 will also prevent 
oxidation of carotenoids but causes bleaching of anthocyan- 
ins (Sian & Soleha, 1991). 
Supplemental antioxidants from natural sources such as 
herbs and spices are effective in conserving foods from 
oxidation. Many plant extracts have antioxidant activity: 
rosemary, sage, thyme, oregano, ginger, turmeric, cloves 
and bay leaves all are active in descending potency (Loliger 
et al. 1996). Different compounds have very different 
activities. For example three components of thyme extract, 
thymol, carvacrol and p-cymene-2,3-diol, were decreas- 
ingly resistant to thermal stress in a lard model (Ternes et 
al. 1995). Mixtures of antioxidants can be obtained from 
natural sources, for example, by mixing with oil and press- 
ing (Aeschbach & Wille, 1993), or by using supercritical 
C02 extraction of antioxidants. This latter technique has 
aroused interest because the solvent involved (COz) is non- 
toxic, non-flammable and of low cost (Tsuda et al. 1995). 
O2 is almost eliminated from the system. Polyphenols can 
be recovered through membrane technologies, for example 
from the waste water from olive oil processing (Tragardh, 
1995). It is presently poorly understood whether compounds 
from this or other fruit and/or vegetable sources have 
antioxidant ability in vivo similar to that they demonstrate 
in vitro and therefore could potentially contribute direct 
health benefits. 
6.4. Conclusions 
The food industry has long experience in the control of 
oxidative damage in foods and this experience can be used 
to advantage for the protection of food antioxidants which 
are beneficial. Some of these, such as vitamins C and E and 
0-carotene are known, and strategies for their protection in 
foods are already exploited by many food technologies. 
However, there are many compounds with antioxidant 
activity which may, or equally may not, have biological 
activity. Since oxidation cannot be eliminated completely, 
efforts must be made to identify those antioxidants which 
are important to health, and in what form they are most 
useful. This requires that more information must be 
obtained in the much neglected field of their bioavailability 
as well as on their bioactivity. With this kind of information, 
food technology strategies for the preservation of those 
antioxidants which are beneficial to health could then be 
applied in a cost-effective manner. 
7. Critical assessment of the science base and conclusions 
7. I .  Identijcation of criteria 
The foregoing sections have surveyed the science base that 
underpins the argument that oxidative damage is a signific- 
ant causative factor in the development of human diseases; 
that antioxidants are capable of preventing or ameliorating 
these disease processes; that the administration of antiox- 
idants to human subjects is safe; and that food technology 
can adapt to meet the needs for nutritional quality and safety 
in the use of antioxidants in foods. It is now necessary to 
evaluate clearly what the impact of this survey is on the 
question of whether an identified specific antioxidant nutri- 
ent can be said to positively affect function and have a risk- 
reducing role. This must involve consideration of whether a 
cause-effect relationship can be established between a 
dietary antioxidant and a health benefit, and what is the 
optimum level of intake of the antioxidant in conferring that 
benefit. 
There are four questions the answers to which are 
considered to be fundamental to providing the required 
critical assessment. 
(1) What is needed to establish that free-radical events are 
involved in detriment to health which eventually can be 
associated with the pathology of an identified disease? 
(2) What is needed to establish that antioxidants have 
specific health benefits? 
(3) What is needed to make a claim about the functional, 
nutritional or health benefits of antioxidant nutrients? 
(4) What is needed to bring an antioxidant product to the 
market? 
The technology base is very relevant because it is 
important, in bringing a product to the market, that the 
active ingredients in the food are still active when the 
consumer consumes them. A further matter also needs 
careful consideration. There is a clear difference between, 
on the one hand optimizing health, by improving intake of 
food constituents, and on the other hand preventing disease, 
although the boundaries between these two objectives are 
not clear-cut. Furthermore, the difference between an effect 
of a nutrient as a food, and its pharmacological effect, 
usually at a higher level of intake, needs to be borne in 
mind. It is important to distinguish between healthy 
products which optimize well-being and health, and those 
which may be capable of preventing disease. A single 
functional food is unlikely by itself to prevent disease; if 
it were to do so it would be at a very high level of dietary 
Defence against reactive oxidative species SlOl 
intake and questions of toxicity might become important. 
The disease is the paradigm, the ‘experimental model’, by 
means of which it is possible to determine the importance to 
human subjects of the nutrient. Antioxidants appear to be 
useful for optimizing well-being, such as in ageing and in 
simple stress situations, not preventing disease. The future 
emphasis for functional foods that contain antioxidants must 
be in providing a suitable level of intake that enhances well- 
being and health. A physician examines a patient by a set of 
established signs, as a result of which the patient is pro- 
nounced ‘well’. There is, however, a category beyond this 
which may be referred to as ‘well-being’; this can be defined 
by objective criteria (McDonald & Newell, 1996; Spilker, 
1996). The optimal level of intake of an antioxidant might 
be demonstrated to be higher than that which is capable of 
being delivered by conventional food, in which case the 
‘functional food’ might have the level of the antioxidant 
enhanced during manufacture by fortification or some other 
means. 
The eventual goal of all this is to determine whether 
specified foods can be considered as ‘functional foods’ in 
that they may be able to confer health benefit following their 
consumption. For the purposes of this discussion, a func- 
tional food is considered to be a food which delivers a 
physiological benefit, and description of it should convey 
unambiguous information that is without deception to the 
consumer about physiological or health benefit. In order that 
a claim about health benefit can be made, in an ideal world 
information should be available, which can be critically 
substantiated from the literature, which establishes the 
following criteria, each of which, although inter-related 
with the others, should be individually satisfied. 
Criterion 1. A plausible and validated basic science 
rationale for: (a) the involvement of free radicals in those 
biochemical and cellular processes which have been shown 
to lead to detriment to well-being and health, and to 
specified human diseases; and (b) the involvement of dietary 
antioxidants in the prevention of these free-radical-invol- 
ving biochemical processes. This should include results 
from studies carried out in vitro, in cells in culture, in in 
vitro/ex vivo models, and in animal models. 
Criterion 2. The existence of human population epi- 
demiological data which demonstrate a statistically vali- 
dated inverse relationship between intake (or preferably 
serum concentration), of individually specified antioxidants 
and the risk of, or mortality from, particular diseases. 
Criterion 3. The existence of prospective statistically 
validated epidemiological evidence that links intake (or 
serum concentration), of identified antioxidants at an early 
stage of the disease process, with risk of human disease 
which may develop some time after the exposure to the 
antioxidants. In such studies both intermediate end-points 
that have been clearly shown to predict subsequent disease, 
as well as final end-points, may be used. 
Criterion 4. The existence of biomarkers for evaluating 
free-radical events in human subjects, and the modulating 
effect on them of antioxidants, which are of interest in 
maintaining well-being as well as the balance between 
health and disease. This will include validation of biomar- 
kers, which must preferably be methodologically uncom- 
plicated, by inter-laboratory studies of the same material 
which has been shown, when investigated in different 
laboratories, to give the same answers, preferably by more 
than one method. A further requirement is that the chosen 
biomarker must be directly relevant, that is it must have 
functional significance; the biomarker must have been 
shown by unequivocal techniques to have some significance 
to both function and the health maintenance or disease risk 
to which it is linked. 
Criterion 5. The existence of statistically validated inter- 
ventional human evidence in large groups of human subjects 
(a) which clearly shows that enhancement of intake of 
specified antioxidants is associated with improvement in a 
valid index of well-being and health, or a lowered risk of 
subsequent disease; (b) which demonstrates optimal levels 
of intake of antioxidants, derived from indices measured by 
chosen biomarkers. This would imply that such biomarkers 
have been established which demonstrate a valid relation- 
ship between intake of the antioxidant and the index 
evaluated by the chosen biomarker(s). 
Criterion 6. The existence of clear evidence that the 
intervention that is proposed with an antioxidant nutrient 
is safe. This will include evidence that a conclusion as to 
safety applies with equal force to all groups in the popula- 
tion, including those that are indulging in behaviour which 
might be expected to increase the risk of the disease 
concerned. 
These are clearly extremely stringent criteria. What is 
required in coming to a conclusion as to the health benefit of 
antioxidants is to evaluate the ‘state of the art’ with respect 
to them, and to come to a conclusion as to how and to what 
extent these criteria are satisfied at present. 
7.2. Critical evaluation of the present knowledge base 
Each of the foregoing sections 2-6 has examined in depth 
one aspect of the science database that exists concerning the 
discussion here. The following conclusions are derived from 
those given in detail in the appropriate section. 
An imbalance of 
ROS and antioxidant defence systems may lead to chemical 
modifications of biologically relevant macromolecules. This 
imbalance provides a logical pathobiochemical mechanism 
for the initiation and development of several disease states. 
Experimental data obtained in vitro provide evidence that 
antioxidants function in systems that scavenge ROS and that 
these are relevant to what occurs in vivo. The relevance in 
vivo of these observations depends inter alia on knowledge 
of the uptake and distribution of the antioxidant within the 
human body, and on what tissue levels of the antioxidant 
may be expected in relation to dietary levels. Epidemiolo- 
gical studies show a correlation between consumption of 
foods rich in antioxidants and a decreased risk of several 
diseases. In particular, diets rich in fruit and vegetables are 
associated with low risk of several diseases and antioxidants 
are among the responsible constituents of such a diet. Data 
on antioxidant supplementation are contradictory and 
further research is necessary to establish whether supple- 
mentation beyond normal dietary intake levels is of benefit. 
There is some way to 
go until validated precise methods are available for 
measuring biomarkers of oxidative damage in human 
7.2.1. Conclusions from section 2. 
7.2.2. Conclusions from section 3. 
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subjects in vivo under minimally invasive conditions. With 
respect to oxidative damage to DNA, HPLC and GC-MS 
methods have both merits and limitations. Oxidation 
artifacts also arise in sample preparation and in derivatiza- 
tion of semi-purified samples. Lipid oxidation products in 
plasma are best measured as isoprostanes or as lipid 
hydroperoxides using specific HPLC techniques. Develop- 
ment of isoprostane measurement will advance specificity 
and precision and will enable measurement of lipid 
peroxidation products in urine, which will give a measure 
of whole-body lipid peroxidation. Measurement of hydro- 
carbon exhalation is a technique fraught with artifacts and is 
unsuitable for human studies. The measurement of oxidative 
damage to proteins has some potential but such methods 
have not been effectively exploited. Measurement of 
metabolites derived from RNS has potential, but at present 
there are many confounding factors which restrict its use. 
7.2.3. Conclusions from section 4. Epidemiological 
studies support the hypothesis that the major antioxidant 
nutrients vitamin E and vitamin C, and @-carotene, which 
may or may not be acting as an antioxidant in vivo, may play 
a beneficial role in prevention of several chronic disorders. 
More research is needed on the impact of other non-nutrient 
compounds, such as other carotenoids and flavonoids, on 
human health. In general, human intervention studies using 
hard end-points are the gold standard. Trials are restricted 
mainly to the major antioxidants and do not allow firm 
conclusions because of inconsistent findings, an insufficient 
number of studies and the use of varying doses. However, 
there is evidence that large doses of /3-carotene may be 
deleterious to the health of certain subgroups of the 
population such as heavy habitual smokers. In functional 
food research, preventive trials with intermediate end-points 
may be of help for testing the efficacy of antioxidants. 
Bioavailability studies and dose-finding studies in combina- 
tion with the development and application of biomarkers are 
required for a successful research strategy. 
Vitamin C is safe at 
levels of supplementation up to 600 mg/d, and higher levels, 
up to 2000 mg/d, are without risk. Vitamin E has a very low 
human toxicity and an intake of 1000 mg/d is without risk; 
3200 mg/d has been shown to be without any consistent risk. 
Large intakes of 0-carotene must be viewed with caution 
because they have been shown to confer detriment to a 
population at high risk of lung cancer when administered 
after many years of high-risk (smoking) behaviour. Until 
further work clarifies the situation in heavy smokers with 
respect to taking supplements, larger doses should be 
avoided by such individuals. There is little reliable 
information about the human toxicology of flavonoids and 
related non-nutrient antioxidant constituents of the diet. A 
key question is whether these substances are taken up by 
human subjects and distributed to the tissues in quantities 
sufficient to confer biological effect. 
The food industry 
has long experience in the control of oxidative damage in 
foods and this experience can be used to advantage for the 
protection of food antioxidants which are beneficial. Some 
of these, such as vitamins C and E and 0-carotene, are well 
known, and strategies for their protection in foods are 
already exploited by food technologies. There are, however, 
7.2.4. Conclusions from section 5. 
7.2.5. Conclusions from section 6. 
many compounds with antioxidant activity which may, or 
equally may not, have biological activity. Since oxidation 
during manufacture cannot be eliminated completely, 
efforts must be made to identify those antioxidants which 
may be important to health and to discover in what form 
they are most useful. This requires that more information 
must be obtained in the much neglected field of their 
bioavailability as well as of their bioactivity. With this 
information, food technology strategies for the preservation 
of those antioxidants which have been shown to be 
beneficial to health can be applied in a cost-effective 
manner. 
7.3. Evaluation of criteria 
By using what is revealed in section 7.2, it is now possible to 
evaluate the criteria set out in section 7.1. 
Criterion 1. There is excellent scientific evidence, derived 
from several kinds of investigation, for the involvement of 
free-radical events, either as initiating cause of, or at a later 
stage in, biochemical and cellular processes that lead to 
health detriment. Antioxidants that are consumed in the 
human diet are involved in modulating these free-radical- 
involving events and, thus, they promote health. Valid 
animal models exist for some forms of cancer and these 
have been used to demonstrate an apparent preventive effect 
of some antioxidants against the development of cancer, 
which gives general support to the contention of health 
benefit and cancer prevention by antioxidants. There is no 
acceptable animal model for arteriosclerotic cardiovascular 
disease. However, there are models which reproduce some 
aspects of atherosclerosis and limited studies with these 
support the view that vitamin E may have a role with other 
factors in delaying the arteriosclerotic process. 
Criterion 2. There is human epidemiological evidence for 
an inverse association between intake of antioxidant 
nutrients, or the fruits and vegetables that contain them, 
sometimes supported by measures of serum concentration, 
and risk of specified diseases in the population. Although 
there are some instances of lack of such correlations being 
reported, most studies support this conclusion. The validity 
of many studies would have been greatly strengthened by 
inclusion of measures of serum concentrations of the anti- 
oxidants under study, and the validity of the conclusion 
varies in strength for the individual antioxidants under 
consideration. 
Criterion 3. There is abundant prospective epidemio- 
logical evidence for a clear correlation between dietary 
intake of fresh fruit and vegetables and a lowered 
subsequent risk of cancer. Some data also show a similar 
correlation with vascular disease. This is a widely accepted 
view and a claim that increased fruit and vegetable intake is 
associated with lowered incidence of some forms of cancer 
and atheromatous cardiovascular disease is entirely valid. 
Although it is generally thought that this health benefit is 
conferred by the antioxidant nutrient and non-nutrient 
substances in fruit and vegetables, no conclusive proof of 
this contention exists and much confusion has been caused 
by statements to this effect; data that show an association 
between high serum levels of specified antioxidants and 
lowered disease incidence provide no answer to the question 
Defence against reactive oxidative species S103 
because the antioxidant may merely be a marker for some 
active agent derived from fruit and vegetables, or a lifestyle 
difference associated with high fruit and vegetable intake. 
The use of ‘cancer’ or ‘cardiovascular disease’ as bio- 
markers of free-radical causation, or antioxidant efficacy, 
are also unreliable because both diseases are multifactorial 
and develop over a long period of time with the possibility 
of multiple inputs into their aetiology, in which antioxidants 
may be only one relevant factor. There is some evidence, 
particularly with respect to cardiovascular disease, that links 
very high intakes of vitamin E, derived from food supple- 
ments, with a dramatically lowered incidence of disease. 
However, the likely level of intake in this case is beyond 
what might be feasibly obtained from the diet, and at normal 
dietary levels of intake there appears to be little health 
benefit in this respect. Such an effect could, however, be 
obtained by the consumption of a functional food fortified to 
contain a high level of vitamin E. 
Criterion 4. At the present time biomarkers exist for 
evaluating oxidative damage to DNA and PUFA; some 
biomarkers for oxidative damage to proteins also exist. 
However, there are many anomalies with respect to these 
biomarkers in that there are both internal inconsistencies in 
measurement of the same material by different methods, and 
external inconsistencies in that some laboratories report 
values that differ widely from those obtained elsewhere 
using apparently similar methods. There is a great need for 
validation studies in which methodology is tested within the 
same laboratory, but also most importantly between differ- 
ent laboratories which must be able to obtain measurements 
that are consistent with the results of others using the same 
material. The predictive value of the biomarker in evaluat- 
ing its relevance to the aetiology of a particular disease also 
requires validation. Only when this kind of validation has 
been done and all experts agree as to methodology will it be 
possible to utilize the methods in a new generation of human 
studies, which will assess the quantitative relationship 
between antioxidant intake and health benefit in human 
subjects. 
Criterion 5. The results of intervention studies have been 
very mixed and at present the situation is confused. There 
are intervention studies in specified populations from which 
some conclusions can be drawn. However, it is not valid, 
and indeed may be highly dangerous, to extrapolate to other 
populations. For example, intervention studies in China 
have used end-points which relate to a particularly high 
natural incidence locally of a particular cancer; the observed 
data are of interest insofar as they refer to a particular cancer 
in a specific location. The fact that the incidence of that 
cancer elsewhere is very low implies that there are other 
factors involved which may prevent widening the conclu- 
sions from China to other locations. Second, the trials 
involving @-carotene supplementation in smokers should 
only be perceived as applying to heavy smokers and must 
not be applied to other sections of the population who do not 
smoke or who only smoke moderately. A further disadvan- 
tage of present interventional evidence is the fact that, 
because cost considerations have driven experimental 
design, individual antioxidants have often not been exam- 
ined but instead a cocktail of several has been employed. 
There are no valid studies that demonstrate optimal levels of 
antioxidant intake in human subjects, and no data exist 
concerning dose-response relationships of nutrient intake 
and biological efficacy. Thus, this criterion may prove to be 
too stringent, although it is important to identify some kind 
of ‘gold standard’ in this respect. In order to give informed 
advice as soon as possible about satkfaction of this criterion 
it is necessary to shorten the time that is required to conduct 
and evaluate human studies because those that rely on final 
end-points are very long and extremely costly to carry out. 
The development and use of intermediate end-points that 
give genuine information about the final end-point must, 
therefore, be an important consideration. 
Criterion 6. There is excellent evidence that antioxidant 
nutrients are safe and can be included in the food of human 
subjects up to quite high levels without discernible risk. It is 
necessary to cite some specific cautions, for example, in 
administering large levels of vitamin E to persons with 
blood coagulation disorders, and @-carotene to heavy 
smokers; such caveats are, however, rare, specific and 
easily identified. There is less certainty with respect to 
non-nutrient antioxidants and, if these substances are 
shown to have potential functional health benefit, then it 
will be necessary to devote attention to their safety. 
7.4. Final conclusions 
(1) There is evidence that mechanisms that involve free 
radicals are implicated at some stage of the development of 
human diseases, and that the maintenance of well-being 
depends on the supply through the diet of antioxidant 
nutrients and @-carotene which modulate free-radical pro- 
cesses in vivo. If it is shown that non-nutrient antioxidants 
are biologically available then they too may contribute to 
the total antioxidant effects of the diet in vivo, as well as 
contributing antioxidant potential during processing, 
storage and in the gastrointestinal tract. 
(2) Present epidemiological evidence is incomplete but in 
general it supports the basic hypothesis that antioxidant 
nutrients contribute to well-being and health. There is no 
evidence to the contrary which would negate this conclu- 
sion. There is minimal similar evidence with respect to the 
non-nutrient antioxidants. 
(3) The development of biomarkers for use in human 
studies is well advanced but biomarkers that are becoming 
established need critical evaluation before they can be used 
in a new generation of human studies to examine and 
evaluate a quantitative cause-and-effect relationship 
between antioxidant intake and health benefit. 
(4) There are few reliable human intervention studies 
which establish cause-effect relationships, and there is no 
evidence which shows clearly the optimal amounts of 
nutrient and non-nutrient antioxidants that are needed in 
the human diet. The identification and development of 
intermediate end-points for evaluating the effect of 
intervention needs further careful work. 
(5) Increasing human dietary intake of antioxidants is safe 
and without undesirable side-effects except in rare well- 
defined instances. 
(6) There is a need to ensure that measures adopted by 
food technologists in the processing of foods maintain the 
antioxidant content of the food, and that the antioxidants are 
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still active at a suitable level when the food is consumed by 
the public. If it can be shown with certainty that a certain 
level of antioxidants in the food is associated with health 
benefit it may be necessary for food producers to consider 
means of enhancing the content or form of the antioxidant 
up to or beyond that usually found in the natural food. 
8. Recommendations for future research 
8. I .  Introduction 
The foregoing section 7 has compared the available 
scientific database with the evidence that is required to 
achieve scientific consensus as to what may be needed in 
order to make a specific claim about the role of antioxidants 
in maintenance of health and well-being. This enables the 
identification of areas where further research is required. 
Improvement in dietary antioxidant intake in human popu- 
lations is expected to result in lowering of the risk of a 
number of degenerative diseases. While desirable as an 
ultimate objective per se, the impact on public health and 
the resultant decrease in health-care costs make it impera- 
tive that substantial sums of money should be spent on 
research in this important area. 
8.2. Specijic recommendations 
Specific recommendations for further research are 
warranted in each of the areas covered by the foregoing 
sections 2 to 5. With regard to section 6 which deals with the 
role of food technology, there is no particular direction that 
research needs to take at the present time. Developments in 
food technology will be based on, and adapt to, nutritional 
recommendations resulting from biologically driven work. 
For example, if it is found that the bioactivity of certain 
flavonoids is high, then steps will have to be taken to 
preserve, or even enhance, the amounts of these compounds 
in food products. Similarly, if glycosides of certain 
compounds prove to be more bioavailable than the free 
antioxidant then similar considerations will apply to the 
handling of glycosidic derivatives by food technologists to 
maximize their content in the food. 
8.2.1. Oxidative damage and antioxidant defence systems 
of the human organism. It is axiomatic to the present 
considerations that prooxidants cause, or are implicated in 
the development of, human disease. Direct measurement of 
prooxidants in vivo is difficult or impossible. It is imperative 
to establish which are the critical free-radical ‘hits’ that are 
the relevant ones; for cancer, which of the multiple 
modifications of DNA caused by oxidative insult are those 
that lead to detriment; for atherogenesis, what is the relative 
relevance of protein and lipid modifications to LDL which 
contribute to the process, and what is their relationship to 
the overall multifactorial process of arteriosclerosis? Are 
the processes examined really relevant to the disease 
causation? For cancer, there is strong evidence that 
prooxidants are involved in the initiation stage of the 
complex process that leads to disease. But what is the 
relevance of the different forms of oxidative damage to the 
process? Investigation of this should clarify the role of 
different antioxidants in controlling carcinogenesis. We 
need simpler and more specific methods to track ROS both 
in the initiation and progression of the cancer process. 
Studies on free-radical involvement in atherosclerosis need 
to focus more clearly on the relevance of oxidative damage 
to other factors involved, and on the relative importance of 
each to the overall complex biochemical process. Non- 
invasive techniques need to be developed to study these 
phenomena in human subjects in vivo and this applies 
particularly to the field of eye diseases which do not readily 
lend themselves to direct investigation. We need to identify 
which are the important antioxidants in terms of the 
maintenance of health, and what is their relationship to 
one another. We need to clarify whether it is the antioxidant 
role of the substance that is important, or whether it is some 
other function, and the possible non-antioxidant effects of 
antioxidants, in particular with respect to modulation of 
gene expression, also need further research. We need to 
know whether there are combined effects of synergy or 
antagonism both with respect to the antioxidants themselves 
and to other food components. The primary aim is to 
identify the active components in the overall system that 
promotes health. With respect to single antioxidants there is 
a need for more information regarding regeneration of 
vitamin E from its radical under cellular conditions, and the 
role of @-carotene in apparently exacerbating the cancer 
process, when given at a late stage to heavy smokers, needs 
investigation. 
8.2.2. Ex vivo methodologies for quantitating and validat- 
ing damage in vivo to biological macromolecules. Before 
meaningful work can proceed on providing evidence of the 
level of antioxidants needed to maintain health and well-being, 
it is necessary to refine and validate methods that are already 
available for measurement of oxidative damage in human 
subjects in a non-invasive manner. This will enable real 
measurement of variables related to oxidative damage and its 
attenuation by antioxidants to be made. With respect to 
biomarkers for oxidative damage to DNA, methods available 
need to be developed further to prevent oxidation during work- 
up, and formation of artifacts during derivatization of samples, 
and careful validation studies in a number of different 
laboratories need to be undertaken using identical test material 
and methodology. Studies of mitochondrial, as opposed to 
nuclear, DNA may prove to be of value because there is some 
evidence that suggests that mitochondrial DNA oxidation 
correlates with other variables of oxidative damage. Similarly, 
for biomarkers of lipid oxidation the relatively new isoprostane 
method needs development and comparison with older 
established, but less reliable, methods, and this needs to be 
examined both in plasma and urine as well as other accessible 
biological material. Validation in many centres by measure- 
ment of oxidative damage in the same biological material 
needs to be undertaken using the same methodology. There is a 
somewhat longer-term need for development of techniques to 
be used ex vivo as measures of protein oxidation in vivo, which 
will, however, probably be able only to reflect the difference at 
a steady state between damage and repair. It is possible that the 
present early indications of biomarkers of RNS may be capable 
of development into useful methodology. 
8.2.3. Nutritional options modulating oxidative damage. 
For proper epidemiological research, as well as for human 
intervention studies, it would be desirable to put special 
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emphasis on the following. (1) Chemical analysis of the 
antioxidant content of foods so that more realistic food 
composition tables can be compiled; ideally this should take 
account of agricultural practices, industrial processing and 
food preparation. (2) Studies of bioavailability of anti- 
oxidants from the diet, and the factors that influence the 
absorption, distribution and tissue uptake of the compounds 
and the likely impact of the antioxidants on metabolic 
processes. This will include studies of the metabolism of 
antioxidants and the possible metabolic interactions 
between them. (3) Development and validation of biomar- 
kers of intermediate end-points, both biological response 
markers and early disease markers, and emphasis on the 
relevance of the biomarker to the disease end-point as well 
as the disease process. (4) Application of the validated 
biomarkers of intermediate end-points in randomized 
controlled trials testing the efficacy of antioxidants in 
functional foods for the maintenance of health and well- 
being. 
8.2.4. Safety implications of nutritional enhancement of 
antioxidants. The detailed evidence that is already avail- 
able which demonstrates that vitamin C and vitamin E are 
safe at quite high levels of inclusion in the human diet, 
means that it is unnecessary to recommend further work in 
this area. The safety of @-carotene was not questioned 
before the results of the Finnish and American intervention 
studies, which showed an apparent exacerbation in the 
incidence of lung cancer in heavy smokers who were given 
supplements of @-carotene. This observation needs urgent 
clarification, and this should also include work on the safety 
of other carotenoids which have been shown to have 
biological activity in human subjects. With respect to the 
flavonoids and other polyphenols, it is likely that their 
bioactivity will be explored, and the key question of their 
bioavailability clarified, in the near future. It will be 
necessary to examine the safety of such bioflavonoid, and 
other similar compounds, which may be shown to have 
bioactivity in human subjects, as information becomes 
available about their bioactivity. 
8.3. Priorities for the recommendations made 
The most urgent requirement for further research is the 
validation of available biomarkers of oxidative damage. 
Much useful work has been done already but several 
anomalies remain and new questions have emerged. 
Before these biomarkers can be used, in particular as 
biomarkers of intermediate end-points, in a new generation 
of human studies, which especially need to assess the level 
of inclusion of antioxidants in the diet that is optimal for 
health and well-being, it is necessary to engage in a 
programme of validation of the biomarkers that are avail- 
able. These validation studies will also necessitate the 
inclusion of studies on the analysis of antioxidants and 
their metabolites. Three types of validation are essential: 
first there is a need for comparison of results obtained in the 
same laboratory on identical material using different but 
complementary methodology so that any numerical 
differences in the results obtained can be eliminated or at 
least minimized. Different methods sometimes appear to 
give different results for what at first sight should be the 
same measurement by different means. Where numerical 
differences remain following evaluation, there must be clear 
reasons given as to the scientific explanation of the differ- 
ence; for example, the different methods may be measuring 
slightly different aspects of the same oxidative damage. 
Second, there is a need for comparison of results obtained in 
as many different laboratories as possible of identical 
material which is exchanged between participating labor- 
atories, each of which should use as many agreed methods 
as possible to assess the degree of oxidative damage in the 
samples employed. Third, there is a need for a different kind 
of validation, which is that measurements made must be 
shown to be clearly linked to those phenomena which give 
rise to disease in human subjects. For example, is the DNA 
oxidative damage that is measured a real indicator of the 
involvement of such damage in mutagenesis and eventual 
carcinogenicity? Is the oxidation of LDL a reliable indicator 
of atherogenesis and eventual vascular disease? The devel- 
opment of a disease must be the ultimate paradigm by which 
the relevance of a biomarker is judged. 
As a logical second stage of the work described in the 
foregoing paragraph, the validated and accepted biomarkers 
will be used in a new generation of human studies. These 
need not be as lengthy or time-consuming, and thus not as 
expensive, as previous prospective epidemiological inter- 
vention studies, because the use of intermediate end-points 
should enable answers to key questions to be obtained 
considerably more quickly than in earlier studies whose 
end-points were disease phenomena occurring many years 
after the initiation of the study. These new studies will 
provide, for the first time, rigidly controlled evidence of the 
benefit to be gained from antioxidants in the human diet, and 
will enable quantitation of the optimal levels of intake of 
antioxidants. In this connection, care must be taken to 
ensure that the importance of the antioxidant contribution 
of the whole diet, as distinct from that of each individual 
antioxidant, will be evaluated. 
The proposals for further research set out in section 8.2 
will need to be addressed as and when funds are available, 
but this should be done at the same time as the major 
programme of research elaborated in the first two para- 
graphs of this section. The proposed work set out in the first 
paragraph could be set in motion with minimal delay and it 
is anticipated that preliminary results could be available 
within 2 years of its inception, with reliable final results 
being available shortly thereafter. The interventional studies 
in human subjects that are proposed in the second paragraph 
could commence at the end of 3 years and results would 
begin to accumulate within 5 years of the initiation of the 
studies. 
Although it is possible to be quite specific with respect to 
the objectives and proposed methodology of the research 
that is envisaged, and the time-frame within which specified 
outcomes may be expected to be achieved, it is beyond the 
capabilities of those concerned with this report to attempt to 
evaluate the costs that might be involved. Research costs are 
a highly volatile quantity and there is considerable variation 
in cost that might be expected even within different institu- 
tions of a single Member State of the European Union. Cost 
comparisons between different Member States are even 
more difficult because labour costs, and cost of delivery of 
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research, differ very widely. It would be  invidious to  
attempt to identify locations where the research might be 
carried out more cheaply than in another, and it is the 
considered view of this group that money identified by the 
European Union for supporting this research should be 
made available on the usual competitive basis, with invita- 
tion of specific proposals from researchers concerned with 
their own specific areas of expertise. These can then be  
assessed both with respect to  their scientific merit, as well as 
their cost, and appropriate awards of money made on this 
basis, which follows accepted practice in all Member States 
of the Union. 
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